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ABSTRACT
The 26th Antibody Engineering & Therapeutics meeting, the annual meeting of The Antibody Society
united over 800 participants from all over the world in San Diego from 6–10 December 2015. The latest
innovations and advances in antibody research and development were discussed, covering a myriad of
antibody-related topics by more than 100 speakers, who were carefully selected by The Antibody Society.
As a prelude, attendees could join the pre-conference training course focusing, among others, on the
engineering and enhancement of antibodies and antibody-like scaffolds, bispeciﬁc antibody engineering
and adaptation to generate chimeric antigen receptor constructs. The main event covered 4 d of scientiﬁc
sessions that included antibody effector functions, reproducibility of research and diagnostic antibodies,
new developments in antibody-drug conjugates (ADCs), preclinical and clinical ADC data, new
technologies and applications for bispeciﬁc antibodies, antibody therapeutics for non-cancer and orphan
indications, antibodies to harness the cellular immune system, building comprehensive IgVH-gene
repertoires through discovering, conﬁrming and cataloging new germline IgVH genes, and overcoming
resistance to clinical immunotherapy. The Antibody Society’s special session focused on “Antibodies to
watch” in 2016. Another special session put the spotlight on the limitations of the new deﬁnitions for the
assignment of antibody international nonproprietary names introduced by the World Health Organization.
The convention concluded with workshops on computational antibody design and on the promise and
challenges of using next-generation sequencing for antibody discovery and engineering from synthetic
and in vivo libraries.
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; ADC, antibody-drug conjugate; AE, adverse
events; AML, acute myeloid leukemia; BiTE, bi-speciﬁc T cell engagers; bsAb, bispeciﬁc antibody; CR, complete
response; CDR, complementarity-determining region; DAR, drug-to-antibody ratio; Fc, fragment crystallizable; HIV,
human immunodeﬁciency virus; IgG, immunoglobulin G; IgVH, immunoglobulin variable region heavy chain; IHC,
immunohistochemistry; mAb, monoclonal antibody; MDR, multidrug resistance; NSCLC, non-small cell lung cancer;
PDX, patient-derived xenograft; PK, pharmacokinetics; RA, rheumatoid arthritis; scFv, single-chain variable fragment;
SCLC, small cell lung cancer
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Monday December 7, 2015, keynote presentations
Joost Melis
Antibodies against Ebola virus: A global collaboration
Erica Ollmann Saphire (The Scripps Research Institute)
opened the conference with an overview of the work of the
Viral Hemorrhagic Fever Immunotherapeutic Consortium
(VIC). The VIC is a global, ﬁeld-wide open collaboration for
antibody therapeutics against Ebola and related viruses.
Filoviruses, such as the Ebola Virus and the Marburg Virus,
have different structural manifestations of their envelope
glycoproteins. These different structures can present hurdles to
effectively create antibody therapeutics, since target sites are
sometimes lost or hidden or serve as potential decoys. Research
has only partially elucidated how viruses can best be targeted.
The human anti-Ebola monoclonal antibody (mAb) KZ52
from a 1995 survivor has been shown to neutralize the virus,
and is able to protect mice and Guinea pigs, but not non-
human primates. In 2011, cocktails combining several anti-
Ebola mAbs protected against infection in non-human pri-
mates, but at least one of these cocktails contained antibodies
that were non- or weakly neutralizing. In 2012, many questions
regarding cocktails needed answers: which type of cocktails is
most suitable, which mAbs are possibly synergistic, which
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mAbs are best to be included or which mAbs could possibly
compete with one another, and which in vitro assays should be
used to select mAbs. These unknowns created a complex prob-
lem that needed a signiﬁcant sample size and input to solve.
This initiated the formation of the VIC, which is now aiming to
map epitopes, ﬁnd predictors of what approach works best and
how to create the best cocktails.
So far, the VIC has mapped the epitopes of 160 anti-Ebola
mAbs and investigated which of these mAbs are able to neu-
tralize the virus and which are able to protect in vivo. Results
showed that some epitopes or locations are more likely to cause
neutralization than others, however the potency to neutralize
does not predict the level of protection.
Additionally, immune effector functions of mAbs might also
be of importance for efﬁcacy. The VIC analyzed the effector
functions related to the 160 available mAbs. The initial analyses
demonstrated a discrepancy between human and mouse results,
and indicated different assays or models were necessary to bet-
ter address the importance of effector functions. The Marburg
virus is the next big challenge for the VIC, which is currently
mapping epitopes of available mAbs for this virus.
The basis and bias of human anti-inﬂuenza -
neutralizing antibody responses
The second keynote lecture was given by Wayne Marasco
(Harvard Medical School). Certain scientiﬁc barriers interfere
with developing a “universal” inﬂuenza vaccine, such as the
antigenic drift that can abolish the binding properties of
broadly neutralizing antibodies (BnAbs). However, very little
changes in the stem domain of the inﬂuenza virus occur in
respect to the globular head domain. The inﬂuenza hemaggluti-
nin (HA) stem is able to elicit a population of antibodies with
broad neutralizing activities, which are also recalcitrant to neu-
tralization escape. BnAb F10 is able to bind all subtypes of
group 1 HA for example. F10 blocks pH-dependent conforma-
tional change and escape from F10 coincides with loss of viral
ﬁtness.
Structural analyses of 38 stem-directed IGHV1-69-sBnAbs
showed several highly conserved amino acids that are essential
for high afﬁnity binding, such as phenylalanine 52 and tyrosine
97–99. These conserved amino acids create promising opportu-
nities for development of BnAbs. IGHV3-30 germline gene-
derived BnAbs contain a complementarity-determining region
(CDR) 3 HC hydrophobic pocket-stabilized epitope and are
effective against group 1 and 2 inﬂuenza A strains, which is
broader than IGHV1-69 BnAbs.
Part two of the presentation focused on the question if it is
possible to vaccinate all individuals of a population, since it is
known that there is quite some variation within populations,
both pre- and post-vaccination. The research herein focused on
the role of genetic VH segment polymorphisms in anti-inﬂu-
enza antibody responses. In a clinical cohort of 85 H5N1 vacci-
nated individuals, genotype/phenotype BnAb responses were
correlated. For this, the expressed antibody repertoire, the effect
of IGHV1-69 genotype on clonal distribution, precursor fre-
quency and copy number were analyzed. In different genotypic
groups, HA stem-directed Abs were monitored over time and
this analysis uncovered a correlation between IGHV1-69
polymorphism and micro-neutralization titers to H5N1. Fur-
ther analyses indicated correlations between IGHV1-69 clonal
signature frequencies, copy number and utilization of the anti-
bodies as BnAbs. Also, immunoglobulin locus wide associations
were assessed and indicated that IGHV1-69 F/L polymorphism,
copy number, and gene duplication are different among ethnic
groups. Genetic background should therefore be taken into
account during vaccine development. Currently, several
approaches toward structured-based universal stem-directed
inﬂuenza vaccines are ongoing. For these current and future
developments, not only serological studies should be used, but
also genotyping and phenotyping signatures. Moreover, estab-
lishing an IGHV haplotype map could prove to be beneﬁcial
for development of BnAbs.
A spatial systems biological view of cancer
Joe Gray (Oregon Health & Science University) then discussed
a spatial systems biological view of cancer. To generate robust
solutions to battle cancer, cancer should be managed as a het-
erogeneous, adaptive system that includes extrinsic proximal
inﬂuences, distal inﬂuences and intrinsic cell biology. This
whole system together dictates cell responses such as prolifera-
tion or apoptosis and the eventual clinical outcome. Cancer
heterogeneity exists at many scales, from tissue level all the way
to molecular structures. Nowadays, imaging technologies allow
us to study and integrate biological systems at multiple scales.
Electron microscopy, conventional and super-resolution light
microscopy, plus anatomical imaging such as positron emission
tomography (PET), magnetic resonance imaging (MRI) and
computerized tomography (CT) together with bioengineering
or computational biology can be integrated to assess and man-
age tumor heterogeneity. Intrinsic tumor heterogeneity can
now be visualized in 3D by using technologies such as light
sheet microscopy and tissue clearing; an example of this was
shown for triple-negative breast cancer.
To address the question if intrinsic tumor heterogeneity is of
functional importance, a cell system using~80 breast cancer cell
lines was used to model many aspects of tumor heterogeneity
such as genomic aberrations, transcriptional subtypes and dif-
ferentiation state. Using MEK and PI3 K inhibitors, it was
shown that the differentiation state of cancer cells changes in
different directions. This is also reﬂected by dose-dependent
changes measured by several “Omics” techniques. Monitoring
and directing these changes creates opportunities to possibly
steer cancer cells into a more homogeneous state that is more
easily treated. This was initially attempted by driving cancer
cells into a state of deep CK19C quiescence. However, once
released from selective pressure, the cells started growing again.
Another option is to prevent cells from undergoing epigenetic
changes, and early results indicate that chromatin modiﬁers
appear to counter resistance-associated epigenomic evolution.
To manage tumor extrinsic heterogeneity, microenviron-
mental signals that inﬂuence tumor cell behavior should be
identiﬁed. Microenvironment microarrays analysis was used to
unravel which signals are important and which ones are not.
Both soluble and insoluble proteins were printed on arrays on
which each spot hosts space for growth of »100 cells. Several
aspects of tumor biology were measured on these spots, such as
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morphology, metabolism, cell cycle, nuclear activity and lineage
status. Some microenvironment proteins (MEPs) profoundly
affected differentiation and proliferation of cancer cells.
Selected MEPs can convert gene targeted therapies into stimu-
latory agents. For example, NRG1 and HGF make neratinib
stimulatory in HER2 luminal cells, which is probably caused by
trimerization of human epidermal growth factor receptors
(HERs). This creates opportunities of receptor multimer forma-
tion to manage extrinsic microenvironment.
Results of immuno-targeted siRNA delivery indicated
siRNA can be used to overcome resistance of cancer cells to
HER2-targeting therapeutics. Anti-HER2-siHER2-NP demon-
strated tumor growth inhibition in mice that were tumor resis-
tant to TM1 and paclitaxel, but became sensitive to these drugs
again by addition of the siRNA therapeutic.
Multispectral super resolution ﬂuorescence microscopy can
be used for direct assessment of receptor complexes on cancer
cells. 3D imaging of cancer cells and the interaction with the
microenvironment can be visualized and indicates where the
receptors are localized on cancer cells. Many of the receptors
are present on long protrusions. Functional assessment of pro-
trusions demonstrated a clear role in receptor transport. Recep-
tors were shown to be moving along these protrusions and
receptors were visualized being transported between cells.
These results initiated the search for protrusion-targeted
therapies.
Beyond biopsies – enabling precision medicine
through antibody-based imaging
The ﬁnal keynote lecture was given by Anna Wu (David Geffen
School of Medicine at University of California Los Angeles).
Molecular diagnostics in oncology are mainly still performed
by making use of in vitro-based technologies, such as biopsies,
blood tests and more novel techniques like circulating tumor
cell detection or next-generation sequencing. Molecular imag-
ing using PET can be used to assess the in vivo situation, ana-
lyzing living tissue in context and performing spatial and
temporal assessments. Since antibody-based therapeutics have
improved signiﬁcantly over the last decade, the use of anti-
body-based products in molecular imaging can be meaningful
for in vivo diagnostics. Several aspects of immune-conjugates
for imaging were discussed, such as targeting strategies, conju-
gation/linker strategies and signal considerations. Improve-
ments in positron-emitting radionuclides have been made for
their use in ImmunoPET, e.g., availability of isotopes with lon-
ger half-lives. Also, optimized antibodies for imaging are now
available; human or humanized antibodies show reduced
immunogenicity, antibody engineering can eliminate unwanted
effector functions and creates options for site-speciﬁc conjuga-
tion. Engineering can also inﬂuence the pharmacokinetics and
targeting capabilities of the antibody-based imaging product.
The use of either intact IgG versus diabody or minibody mole-
cules can greatly affect exposure and clearance, and conse-
quently the level of background activity. For instance, an intact
antibody takes a week to clear from the body while a diabody is
eliminated within 4–7 hours, which effectively means diabodies
can be used for same day imaging. Cysteine modiﬁcation of
diabodies allows site-speciﬁc conjugation and more uniform
products. ImmunoPET can provide info on tumor presence,
cell surface phenotype, target expression for therapy selection,
target occupancy, internalization/catabolism, response to ther-
apy, and mechanistic or quantiﬁcation purposes. Data of a 124I
PSCA-minibody for quantitative immunoPET imaging of pros-
tate cancer and of an 89Zr-DFO-H2 anti-MET minibody mea-
suring c-MET expression as a marker for resistance to anti-
EGFR therapy was presented.
Antibody-based imaging of both cancer cells and immune
cells can shed more light on immune responses, immune cells
subsets, expansion, trafﬁcking and activation. These imaging
techniques can be applied in the ﬁeld of inﬂammatory and
autoimmune disease and cancer immunotherapy for instance.
Since CD8 cytotoxic T cells are very potent immune cells, sev-
eral examples of CD8 T cell quantitation and biodistribution in
tissues were shown: 1) imaging using 89Zr-radiolabeled anti-
CD8-169 cys-diabody successfully showed T cell repopulation
following HSC transplant, 2) imaging of CD8 T cell inﬁltration
in anti-PD-L1 tumor immunotherapy in syngeneic BALB/c
mouse model for CT26 colon carcinoma, and 3) imaging the
massive recruitment of T cells into tumor and lymphoid tissues
upon 4–1BB antibody treatment. This work is now being
extended to CD4 and CD20 imaging.
Track A: Antibody effector functions
Jenny Yeung
The afternoon session on antibody effector functions was
chaired by Paul Parren (Genmab) and Dennis Burton (The
Scripps Research Institute).
Suppression of antibody effector activity during
persistent virus infection
Persistent viral infections are a global health concern, with over
500 million people infected with HIV and hepatitis B and C
viruses. As discussed by David Brooks (Princess Margaret
Cancer Center and University of Toronto), what they all have
in common is a mechanism that evades or circumvents the
immune response, creating an immunosuppressive environ-
ment. Understanding what governs immunosuppression may
help to develop ways in which to restore immune function in
persistent infection.
The comparison of the humoral responses elicited by mice
infected with 2 variant strains of lymphocytic choriomeningitis
virus (LCMV), which induced either an acute infection (Arm-
strong) or a persistent infection (clone 13), led to the elucida-
tion of a mechanism of immunosuppression mediated by
immune complexes. During persistent infection, high total
antibody levels and high levels of immune complexes exist in
tandem with decreased virus-speciﬁc antibody levels, which
result in suppression of antibody functions. Using exogenously
administered cell-depleting anti-CD4 or anti-CD20 antibodies,
it was observed that depletion of target cells was signiﬁcantly
suppressed in persistently LMCV infected wild type mice where
antibody levels were high. Depletion of target cells was restored
in mice with compromised B cell responses and therefore low
antibody levels.
MABS 619
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In vitro and in vivo studies showed that the high amounts of
immune complexes generated in persistently infected wild type
mice led to compromised FcgR-mediated effector functions,
such as macrophage phagocytosis and dendritic cell mediated
cross-presentation. Immune complex formation blocked acti-
vating FcgRs and resulted in suppression of IgG-mediated
effector functions. This suppression of the immune system
function is reversible, as ex vivo cells from persistently infected
mice had decreased levels of antibody on the cell surface after
resting, which subsequently restored phagocytosis. These data
illustrate a new mechanism through which persistent virus
infections can suppress the immune response and have impor-
tant implication for the design of antibody therapies to control
persistent infections.1
George Georgiou (University of Texas) next presented a set
of novel aglycosylated Fc domains with an exquisite ability to
speciﬁcally activate individual Fc-mediated effector mecha-
nisms. Notably, he demonstrated the importance of the long-
disputed signiﬁcance of in vivo complement activation in the
anti-tumor activity of CD20 antibodies.
Functional aspects and therapeutic application of
antigen-dependent formation of IgG hexamers at the
cell surface
Esther Breij (Genmab) presented the Genmab Hexabody
platform, which developed from their earlier elegant work
showing how monomeric IgGs assemble into an ordered hex-
americ structure promotes to activation of the complement cas-
cade.2,3 The understanding of this mechanism can aid or
enhance the efﬁcacy of therapeutic antibodies.4 Formation of
the hexamers is determined by Fc:Fc interactions mediated by
critical residues. Indeed enhanced formation of hexamers as a
result of mutations in key residues can enhance binding to C1q
and enhanced complement-dependent cytotoxicity, which cre-
ates potential for developing more effective therapeutics. The
Hexabody platform can be applied to a large range of antibod-
ies and to different targets.
Death receptor (DR5) is a receptor for TRAIL, which upon
binding to the ligand, initiates an ‘outside-in’ signaling pathway
leading to apoptotic cell death of TRAIL-sensitive cancer cells.
While pre-clinical ﬁndings showed compelling anti-tumor
activity, anti-Death Receptor antibodies have not performed as
well in clinical trials. Cross-linking of DR5 is a key factor for
the anti-tumor activity. Two anti-DR5 antibodies that do not
compete for DR5 binding were developed using the Hexabody
platform and studied in vitro and in vivo: Hx-DR5-03 and Hx-
DR5-07. The potency of the Hx-DR5-03 and Hx-DR5-07 was
enhanced compared to the wild type IgG1 antibodies IgG1-
DR5-03 and IgG1-DR5-07. When used as a combination, the
potency of the HexaBody molecules was enhanced even
further, in a number of different DR5-positive cell lines.
The potency was relatively ratio independent, whereby a
Hx-DR5-03:Hx-DR5-07 ratio of 9:1 or 1:9 was always more
potent than the single antibodies, although a 1:3 or 3:1 ratio
appeared to be optimal. The key element was that it was a mix-
ture of antibodies. To potently induce cytotoxicity, the Hx-
DR5-03/07 combination does not need a secondary cross-link-
ing agent, which is necessary for other anti-DR5 antibodies
(conatumumab and tigatuzumab). In seven of 9 murine xeno-
graft models, the Hexabody combination showed consistently
better potency than conatumumab. The maximal therapeutic
effect was achieved at 0.5 mg/kg (lowest dose tested) or 2.0 mg/
kg. These data demonstrate the therapeutic potential of the
Hexabody platform for potentiating therapeutic antibodies
for the treatment of cancer.
After the networking break, David DiLillo (Rockefeller Uni-
versity) discussed the long-term effects of immunotherapy.
Recent insights showed that next to direct Fc-mediated cyto-
toxic effects, therapeutic antibodies may also induce potent and
long long-lasting vaccine effects. The potential of improving
this aspect, which is mediated via an interaction between anti-
body Fc and the IgG receptor FcgRIIa, provides new opportu-
nities for marrying vaccine and immunotherapy approaches.
Neutrophils kill antibody-opsonized cancer cells by
trogoptosis
Timo K. van den Berg (Sanquin Research and Academic Med-
ical Center) discussed the process of trogoptosis. Antibody-
dependent cell-mediated cytotoxicity (ADCC), mediated by
natural killer (NK) cells and phagocytic cells such as macro-
phages and neutrophils, contribute to the anti-tumor effects of
therapeutic antibodies developed for cancer treatment. Each of
these effector cell types express Fcg receptors (FcgRs) and
form cell-to-cell synapses with their antibody-coated target
cells. NK cells induce target cell apoptosis by release of gran-
zyme B and perforin, and macrophages phagocytose tumor
cells and destroy them through intracellular lysosomal degrada-
tion. How neutrophils kill antibody-opsonized tumor cells was
however not fully understood. As has been previously shown
for macrophages, inhibition of the Signal Regulatory Protein
Alpha (SIRPa)/CD47 signaling pathway potentiated cell death
of opsonized cancer cells by neutrophils.
Formation of a cytotoxic synapse between the neutrophil
and opsonized target was a necessary pre-requisite for neutro-
phil-induced tumor cell death. Blocking SIRPa/CD47 interac-
tion increased synapse formation, a process dependent on
CD11b/CD18 integrin. Live imaging studies showed that neu-
trophils used a trogocytosis-related process, termed trogoptosis
(trogo is Greek for gnaw) to kill antibody-coated tumor cells.
This novel cell death process did not involve anti-microbial
properties of neutrophils, i.e., NAPDH oxidase or cytotoxic
granules release. Neutrophils from these patients with genetic
defects in these pathways were still capable of killing antibody-
coated tumor cells.
During trogoptosis, neutrophils disrupt the plasma mem-
brane of opsonized tumor cells by tearing off pieces at the cyto-
toxic synapse, leading to leakage of cellular contents and
subsequent tumor cell death. Use of pharmacological com-
pounds showed that several signaling pathways were involved
in the triggering of trogoptosis, including the calmodulin, Syk,
PI3 K and MLCK pathways. There was evidence to show that
trogoptosis is a potentially relevant process in vivo as well as in
vitro. Using a murine melanoma model, GFPC neutrophils
could be correlated with death of anti-gp75-opsonized B16F10
melanoma cells in the liver of mice. Furthermore, in biopsies
taken from HER2C breast cancer patients after trastuzumab
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treatment, signiﬁcant inﬁltration of neutrophils was apparent
and these neutrophils contained HER2C intracellular material.
In summary, trogoptosis is a novel form of neutrophil-medi-
ated cell death of antibody-coated cancer cells, which can be
potentiated by disruption of the CD47/SIRPa pathway.
Together this could potentially improve the activity of thera-
peutic antibodies against cancer.
Marie Kosko-Vilbois (NovImmune) continued on this
theme by presenting a bispeciﬁc antibody approach. Bispeciﬁc
antibodies comprising a CD47 binding arm optimized for afﬁn-
ity, a tumor antigen binding arm and an active IgG1 Fc domain
provide a novel means for speciﬁc and enhanced tumor cell
killing.
Track B: Getting to reproducibility in research and Dx
antibodies
Janice Reichert, Andrew Bradbury, Fridtjof Lund-Johansen
As research reagents, commercially available antibodies have
been widely criticized for being poorly characterized, and for
yielding irreproducible experimental results because they are
either not of the correct speciﬁcity or not suitable for the type
of experiment.5 In this session chaired by Andrew Bradbury
(Los Alamos National Laboratory), speakers from the aca-
demic, non-proﬁt and commercial sectors reiterated the prob-
lem, discussed the approaches currently used to ameliorate the
situation, and proposed solutions.
At the crossroads: Getting to reproducible research
antibodies
Andrew Bradbury provided an overview of the nature and
scale of the problems with research antibodies, and suggested a
solution. The research antibody business includes over 300 ven-
dors (as listed on antibodyresource.com) and >2,000,000 anti-
bodies (as listed on CiteAb). Many companies set up their
development or manufacturing sites overseas to take advantage
of cost advantages, and most producers sell their antibodies to
multiple vendors, who add their own labels. The vendors also
buy and sell from each other, and then add their own labels. It
is thus possible to get the same antibody when purchasing from
different vendors. Characterization is expensive (>$200 for a
western blot; >$60 per IHC slide), so data from vendors is
often minimal and historical (i.e., it often does not apply to the
speciﬁc lot purchased). The large number of antibodies against
popular targets (e.g., receptor-type tyrosine-protein phospha-
tase C is targeted by 3255 antibodies; 42 proteins have over
1,000 antibodies; 3483 proteins have 100 or more antibodies)
makes the selection of effective and reproducible antibodies
extremely challenging. Dr. Bradbury noted that substantial
time and money (estimated at >$1.1 billion annually world-
wide) is wasted on bad antibodies. This represents only the cost
of the defective reagents themselves, and takes no account of
the money and time wasted on additional secondary reagents,
or trying to reproduce irreproducible experiments. In fact,
poorly characterized, irreproducible antibodies have been cited
as being one of the commonest causes of publications that can-
not be repeated.6-8 Unfortunately, better antibody characteriza-
tion or ordering from only the best, most reliable
manufacturers may not solve the problem, because even good
antibodies that are well characterized are not deﬁned or
archived forever in a way that allows scientists to unequivocally
use the same antibody as that used in a previous study.
In considering solutions, a key point is that research anti-
bodies are sold on the basis of what they (purportedly) recog-
nize, not their physical identity. Dr. Bradbury made it clear that
antibodies should be well characterized and validated; this is
the solution to poorly functioning antibodies. However, in
order to resolve the problem of irreproducibility, antibodies
need to be expressed recombinantly and identiﬁed by unique
“bar codes,” i.e., their publicly available sequences. This would
address reproducibility issues, as researchers can then repeat/
reproduce experiments with the same reagents as those used in
previous publications. Good binders will become immortal and
never lost, and complete characterization is required only once.
In fact, some non-therapeutic antibody companies are selling
recombinants, but not revealing sequences. These include AbD-
Serotech and Creative Diagnostics (that use in vitro methods),
Biosite, REAﬁnity and ABﬁnity (that generate recombinant
antibodies from immunized animals), Absolute Antibodies
(make recombinant antibodies by synthesising genes from pat-
ent sequences) and AbCam (»5,000 recombinant rabbit mono-
clonals, originally derived by Epitomics).
Dr. Bradbury stated that the problem needs to be solved by
many different constituencies, including the funding agencies,
journals and commercial antibody providers. Funding agencies
can contribute by insisting that all antibodies used in research
are sequenced and recombinantly expressed, with their sequen-
ces published in publically accessible databases. As this is a very
ambitious goal, it will require scientists to be informed of these
requirements with a long lead time (e.g., 5–10 years). Because
of the commercial considerations, it is likely that this would be
best implemented if funding agencies established specialized
centers for binder selection, sequencing and characterization
that would be able to provide well characterized sequenced
antibodies to scientists, much like NCI, or Neuromab.
Publishers can contribute by Insisting that the sequences of all
antibodies used in published papers are disclosed (e.g., within
5–10 years), and that methods descriptions include antibody
concentrations and the buffers used. Antibody sequences would
be best disclosed using an accession number system that could
be cited in publications. Ideally this would be in a separate ﬁeld,
which would allow automatic archiving. He acknowledged that
some companies are not keen on the idea of publishing anti-
body sequences as they are considered intellectual property,
and there are no cheap ways to protect antibody sequences,
since antibodies used in research do not make enough money
to invest in patenting (see the description of Dr. Polakiewicz’s
seminar below). One way to address company concerns would
be the publically funded, specialized centers for binder selec-
tion, sequencing and characterization described above. In this
scenario, once antibodies are derived and characterized, compa-
nies could compete on the production, cost or quality of the
publicly available sequence validated antibodies. Dr. Bradbury
also raised the possibility that technology may be developed that
renders the generation, characterization and production of anti-
bodies so cheap that publication of sequence may not become a
concern. However, he thought this could take some time.
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In conclusion, Dr. Bradbury described progress made by a
number of organizations. The Global Biological Standards
Institute (GBSI) has established a Research Antibodies and
Standards Task Force that will focus on the application of
standards that can advance the quality, efﬁcacy, and reproduc-
ibility of antibodies used in basic and preclinical research and
development. The objectives of the Task Force are to identify
speciﬁc areas where standards for research antibodies are
urgently needed, what types of standards could be designed
and implemented to address these needs, and how these recom-
mendations can be effectively implemented by commercial pro-
ducers and vendors. With The Antibody Society, GBSI is
organizing a meeting at Asilomar in the fall of 2016 for all
stakeholders on the use of antibodies in rigorous and reproduc-
ible research. The Human Proteome Organization (HUPO) has
established an Antibody Standards Committee with the goal to
deﬁne and propose common standards for afﬁnity reagents,
and to engage the broader scientiﬁc community in dialog
around this issue. Ultimately the goal would be to publish
guidelines to be endorsed by publishers that offer guidance to
both antibody users and providers. The Federation of American
Societies for Experimental Biology (FASEB), is organizing
workshops on the use of antibodies in rigorous reproducible
research, and is also planning to publish guidelines on the use
of antibodies to be adopted by researchers.
Use and abuse of antibodies in research and the clinic
David Rimm (Yale University) noted that the problems associ-
ated with antibody reagents sold by some vendors pose a bar-
rier to successful translational research. For example, in a study
reported in 2008,9 the success rates for validation of 5436 anti-
bodies from 51 providers for use in Western blotting and tissue
microarrays was only 49% on average, and ranged from 0 to
100%. Prof. Rimm indicated that this unpredictability as to
whether antibody reagents are suitable for speciﬁc applications
means that researchers must validate the reagents to ensure
that their experiments yield scientiﬁcally rigorous and repro-
ducible data. He then discussed the Rimm Lab’s algorithm,10
which is focused on validation of antibodies for immunohis-
tochemistry (ICH) or quantitative immunoﬂuorescence on par-
afﬁn-embedded tissues, but could be equally valid or modiﬁed
for other antibody-based assays. Although antibody validation
by the end-user is time-consuming, Prof. Rimm emphasized
the need for quantitative analysis, assessment of sensitivity and
speciﬁcity, as well as reproducibility across lots, platforms,
operators and labs. For both ICH and scientiﬁc research appli-
cations, use of monoclonal and preferably recombinant anti-
bodies was recommended. In concluding Prof. Rimm noted
that, although companies should in theory validate antibodies,
the end users are ultimately responsible for the accuracy of
their experimental data, and therefore the quality of the anti-
bodies they use.
Nonspeciﬁc antibodies, what could possibly go
wrong? the Epo R story
Steve Elliott (Amgen) who has extensive knowledge of anti-
bodies targeting the erythropoietin receptor (EpoR), discussed
long-standing problems with these reagents. He discussed the
fact that ﬂawed assumptions and experiments lead to the
reporting of ﬂawed data and conclusions, and a cascade of neg-
ative effects can occur when researchers then attempt to follow
up on the ﬂawed work. As an example of this, Dr. Elliott
reviewed ﬂawed data that suggested erythropoietin stimulating
agents promoted tumor cell growth through activation of
EpoR. Dr. Elliott related that he and colleagues investigated the
speciﬁcity of the anti-EpoR polyclonal antibodies used for the
immunoblotting and immunostaining, and showed that in real-
ity only one was suitable for use in immunoblotting, and none
were suitable for immunohistochemistry.11 Use of these anti-
bodies, however, has continued and led to widespread dissemi-
nation of misinformation about the receptor. Dr. Elliott then
related a more detailed examination of the problem. Of 219
studies of the “EpoR cancer” hypothesis, only 10% were prop-
erly controlled, i.e., used positive and negative control cells or
tissue, used validated reagents and reported data that supported
the conclusions. A total of 140 of the 219 studies included anti-
EpoR antibody data, and only 8 of these were properly con-
trolled, i.e., had EpoR positive and negative tissues or cell lines,
and, for westerns, size markers were used and band matched
the size of EpoR. Notably, none of the studies that reported
results supportive of the hypothesis were controlled. Dr. Elliott
highlighted the speciﬁc problems with many of the studies,
including use of non-speciﬁc anti-EpoR antibodies, inappropri-
ate or insufﬁcient use of controls and the reporting of conclu-
sions that were not supported by the data. He then elaborated
on the difﬁculty of validating antibodies. False-positive results
are common, even with westerns, and may be difﬁcult to detect.
For example, a band on a gel may be the correct size, but the
band may result from off-target binding. In addition, false-pos-
itive data may be tissue speciﬁc. Thus, investigators must be
extremely cautious, always use appropriate positive and nega-
tive control samples and include additional conﬁrmatory data,
e.g., duplicate experiments with a second validated antibody.
Dr. Elliott concluded by stating his view on the topic: In scien-
tiﬁc endeavors it is rewarding to be right. But it takes courage
to admit you are wrong and then correct the record. Failure to
do so may be far more damaging than you realize.
Improving antibody quality by combining novel
technology and classic concepts for research antibody
discovery and development
Roberto Polakiewicz (Cell Signaling Technology) provided the
perspective of Cell Signaling Technology (CST), a commercial
supplier of research antibodies. He ﬁrst acknowledged that
commercial antibodies are getting bad press. One issue is the
economics of the market for research antibodies, which is small
compared to the markets for diagnostic and therapeutic anti-
bodies (»$2.5 bn vs $15 bn and $55 bn, respectively) and com-
posed of over 300 providers that offer over 2.5 million antibody
reagents. Suppliers may be aggregators or re-sellers of the
reagents, and many do not validate their products or provide
validation data. The problems are exacerbated by poor or non-
existent quality-control (QC) systems or technical support. He
then differentiated CST’s approach by noting that their mAbs
are primarily recombinant mAbs and that CST emphasizes
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application validation, QC and technical support. CST does
95% of antibody development and all product-manufacturing
in-house.
Dr. Polakiewicz then discussed the process of making a good
mAb, including product design, antibody capture/isolation, val-
idation, formulation, and the use of appropriate screening
assays at each step. He emphasized that appropriate controls
and testing on multiple applications to verify speciﬁcity are
important, and that each lot must be assessed and compared as
part of the QC process. Such a process requires investment of
scientiﬁc expertise, time and money. Sequenced antibodies
have been proposed as a solution to the problems associated
with research antibodies, but Dr. Polakiewicz noted that plac-
ing the sequences in the public domain jeopardizes the invest-
ment in validation and support because the revenue from each
product is too small to justify costs of patenting (up to $300 k)
and potential litigation. In concluding, Dr. Polakiewicz pro-
vided recommendations that, if followed, could alleviate the
issues associated with research antibodies. In particular: 1) anti-
body suppliers should validate properly, share data (excluding
sequences) and provide customer support; 2) antibody users
should trust companies that validate and share data, follow pro-
tocols suggested by the vendor, use antibodies for recom-
mended applications, seek technical support, avoid purchasing
from large aggregators offering antibodies of unknown origin,
and prefer monoclonals (recombinants, if available); 3) journals
should require precise citation of antibody sources (e.g., catalog
and lot numbers), validation data, and detailed protocols for
experiments involving use of antibodies; 4) independent inter-
net sources should help disseminate data, citations and user
feedback; and 5) academic and funding institutions should
train young investigators on how to ﬁnd and use good
antibodies.
Closing the reproducibility gap with standards and
best practices for antibodies
Global Biological Standards Institute
Leonard Freedman (Global Biological Standard Institute)
made the case that standards facilitate the alignment of consen-
sus-based best practices, reduce variance, and improve repro-
ducibility in biomedical research. He discussed the progress
made with establishing standards for authentication of human
cell lines using short tandem repeat DNA proﬁling, which is a
well-established technique that unambiguously characterizes a
number of different loci in the human genome, but noted that
there are no universally-accepted guidelines or standardized
methods for validation of research antibodies. Dr. Freedman
noted that the Global Biological Standards Institute (GBSI) has
launched a research antibody validation initiative. The
“Research Antibodies: Solutions for Today and Tomorrow”
workshop GBSI is organizing with The Antibody Society, has
the goals to: 1) identify a set of standards to validate research
antibodies, including recommendations for adoption by acade-
mia, industry, funders, and journals; 2) develop recommenda-
tions for an independent proﬁciency certiﬁcation system or
open access user ratings service; and 3) develop recommenda-
tions, timeline, and follow-up plan for the introduction of
sequenced recombinant antibodies as research reagents. In
concluding, he discussed steps that could yield substantial
improvements in preclinical reproducibility rates, including
encouraging vendors to offer only validated reagents (e.g., anti-
bodies, cell lines) and broad utilization of these reagents by
principle investigators; ensuring that research funder policies
require documented use of validated and non-contaminated
reagents and adequate funding to cover these additional costs;
ensuring that procedures to document reagent validation are
required by publishers.12
Reproducibility crisis: Don’t blame the antibodies,
array them
Fridtjof Lund-Johansen (Oslo University Hospital) argued
that researchers may be ignoring a large number of excellent
antibodies. Currently, sales are largely limited to a small num-
ber of reagents that have been used in many publications. How-
ever, there is no evidence that top-cited antibodies are top
performers. To ﬁnd good antibodies with few or no citations,
Prof. Lund-Johansen and co-workers have developed array
technology that allows parallel validation of thousands of anti-
bodies. In Microsphere Afﬁnity Proteomics (MAP), antibodies
bound to color-coded microspheres are used to capture bioti-
nylated proteins from cell lysates. In a multiplexed version of
the protein gel blot, the labeled proteins are denatured, sepa-
rated by gel electrophoresis and eluted into liquid fractions.
The fractions are next incubated with microsphere-based anti-
body arrays, and proteins captured onto the surface of the
microspheres are labeled with ﬂuorescent streptavidin and
detected by ﬂow cytometry. In a separate assay referred to as
Native-MAP, sample proteins are ﬁrst separated according to
subcellular localization and then by size-exclusion chromatog-
raphy to resolve monomeric proteins and protein complexes.
Numerical data from MAP are visualized as line plots that
show antibody capture across the fractions. Different targets of
the same capture antibody are seen as discrete peaks across the
fractions. To discriminate those that correspond to intended
antibody targets and cross-reactivity, an aliquot of each fraction
is analyzed by mass spectrometry. Thus far, the MAP technique
has been used with more than 3000 commercially available
antibodies, and the results show that »10% of antibodies with
no or few citations outperform top-cited products. Attendees
asked whether MAP can predict performance of antibodies in
standard applications such as western blotting and immunohis-
tochemistry (IHC). Prof. Lund-Johansen replied that there is
good correspondence between MAP and protein gel blotting,
and that studies on IHC are in progress. From a theoretical per-
spective, antibodies that perform well in capture are likely to be
high afﬁnity reagents, and since the assay is used both with
native and denatured proteins, one would expect that most rel-
evant epitopes should be covered.
Track A: New aspects of prodrug targeting
Chris Ullman
The second day of the conference opened with a session
chaired by Andreas Pl€uckthun (University of Z€urich) that
focused on Prodrug targeting, addressing the challenge of how
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antibodies and antibody drug conjugates can be engineered to
be more selective for disease tissue.
Protease mediated activation of tissue/tumor-
targeting antibodies and prodrug approaches
Ulrich Brinkmann (Roche) opened this session. The basis of
the approach was an adaption of the use of bi/multi-speciﬁc
antibodies, used to modulate proliferative or inﬂammatory pro-
cesses. There are over 50 different bispeciﬁc formats described
in the literature, which allows the researcher to adjust the size,
valency, ﬂexibility, half-life and biodistribution offering an
overwhelming choice.13 Brinkmann stated that he was not a
believer in one size and one format ﬁts all diseases and all tar-
gets, thus rather than to ask which format is best, it is best to
consider which format is optimal for which disease. Modiﬁca-
tions to the structures of the bispeciﬁc can add additional selec-
tivity so that they become active only at the desired location.
In general, there are 2 groups of bsAbs, those that have an Fc
and those that do not. The non-Fc-containing bispeciﬁcs func-
tion by forming a bridge between T cells and cancerous cell tar-
gets. Examples of these formats are Amgen’s bi-speciﬁc T cell
engagers (BiTEs) or Macrogenic’s Dual-Afﬁnity Re-Targeting
(DART) fragments. A disadvantage of the format is the short
half-life, which may require products to be administered via
continuous intravenous infusion. Inclusion of an Fc confers
advantages of solubility, stability, half-life extension and effec-
tor function, each of which can be modiﬁed by genetic engi-
neering. Puriﬁcation is also easier for Fc-containing molecules.
The production of such multichain bsAb can be improved by
‘knobs-into-holes’ technology, or variations of this theme, to
ensure correct heavy chain assembly.
Dr. Brinkmann offered examples from the Roche Group.
RG7716 (in Phase 1 for wet age-related macular degeneration)
and RG7221 (in Phase 2 for colorectal cancer) were built using
CrossMab technology, which allows correct heavy-light pairing
driven by swapping the CH1 of one heavy chain with the corre-
sponding CL region of the light chain and vice versa. These
antibodies simultaneously inactivate 2 ligands that are modula-
tors for angiogenesis - angiopoietin2 and VEGF-A. The bsAb
binds each ligand with each arm of an IgG-like molecule con-
taining functional Fc region and prevents activation of their
respective receptors, Tie-2 and VEGF receptor kinases. The bis-
peciﬁc format offers advantages as 2 factors are depleted,
thereby allowing treatment of tumors that escape angiogenic
single anti-VEGF treatment.
RG6013 (developed by Chugai), using a common light chain
approach to simplify production, targets FIXa and FX for
hemophilia in a full IgG format. The bispeciﬁc binding brings
together 2 proteins of the same cascade into the same complex
that is necessary for sufferers of hemophilia A who lack factor
VIIIa, which naturally complexes FIXa and FX. The antibody
has advantages over supplementation of FVIII by having a lon-
ger half-life in vivo and is less immunogenic in patients. In
addition, a dual action Fab (DAF) antibody directed at HER1
and HER3, is in Phase 2 clinical trial for head and neck cancer.
This antibody simultaneously blocks HER1 and HER3 through
binding the same variable regions, potentially improving cancer
treatment by inhibition of MAPK and AKT signaling and
growth arrest of pathway-addicted cells. Good afﬁnities against
both molecules have been achieved.
These examples served to demonstrate interesting functional
formats for bispeciﬁcs, but the toxicity associated with some
targets can be problematic. A proposed solution is to enable
local activation of function through protease cleavage, particu-
larly relevant when binding to death receptors or targets that
are also expressed on non-diseased tissue.14 Overexpression of
proteases in tumors can be exploited by activating the binding
capacity of half a bispeciﬁc. Thus, half of the bispeciﬁc tethers
the molecule to the diseased cell, thereby bringing a cleavable
linker in proximity to the protease to allow activation of the
second binding modality. This cleavable disulﬁde-stabilized Fv
format was described for a bispeciﬁc targeting HER3 and cMet,
in which the binding of cMet is driven by a VH and VL domain
at the C-terminus of the heavy chain that is activated through
cleavage by an enzyme (such as MMP2 or 9, urokinase-type-
plasminogen activator or furin). The two anti-cMet variable
domains are linked by a disulﬁde bond (VH 44- VL 100) that
maintains pairing following the cleavage of the protease sensi-
tive linker ((G4S2)2-protease site (G4S2)2) connecting VL to
CH3. The cloaking of the binding site affects on-rate of bind-
ing, but not the off-rate to cMet, and reduces afﬁnity for recep-
tors where there is an absence of protease.
Probody therapeutics redeﬁne the landscape of
antibody modalities in oncology
The theme was continued by Luc Desnoyers’ (CytomX) pre-
sentation “ProbodyTM Therapeutics Redeﬁne the Landscape of
Antibody Modalities in Oncology.” CytomX’s Probody tech-
nology differs by the fact that the antigen binding site of the
antibody is masked with a peptide linked to the N-terminus of
the light chain through a protease cleavable linker and is appli-
cable to therapeutics and imaging.15,16 In the case of anti-EGFR
Probody PB1, the 21–amino acid masking peptide is recombi-
nantly fused to the light chain through a 26–amino acid linker
carrying the 8-residue protease cleavable substrate, ﬂanked by
Gly-Ser–rich peptide linkers. Protease activation of the Pro-
body antibody is tightly regulated, producing binding when
cleaved by tumor-associated proteases, such as urokinase-type
plasminogen activator (uPA), membrane-type serine protease 1
(MT-SP1/matriptase), and legumain, a lysosomal protease
found to be released and active in the acidic extracellular tumor
microenvironment.15 This potentially provides a better safety
proﬁle and speciﬁc examples were described including CX-072,
a protease-cleavable anti-PD-L1 Probody therapeutic. CX-072
has been shown to provide equivalent anti-tumor activity in
mice to that of its parental antibody, while minimizing binding
to peripheral cells through local activation within the tumor,
thereby reducing induction of autoimmune diabetes in NOD
mice caused by the parental antibody. Further examples
included anti-human CD166 Probody drug conjugate (PDC).
CD166 is not an obvious target for an antibody-drug conjugate
(ADC) because it is expressed on normal tissues, but is highly
expressed in many cancers. The anti-CD166 Probody-SPDB-
DM4 therapeutic was selected because it binds human and cyn-
omolgus CD166, but doesn’t bind to the rodent equivalent. It
was well tolerated at 5 mg/kg, with no evidence of on-target
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toxicity, and off-target toxicity typical of SPDB-DM4 noted at
15 mg/kg. This study demonstrates the potential use of Pro-
body drug conjugates for promising and previously inaccessi-
ble cancer antigens through reducing the collateral damage to
normal tissues. A Probody T cell-binding bispeciﬁc (TCB)
platform has also been developed by creating an anti-CD3
Probody bispeciﬁc. T cell engagers have shown efﬁcacy in
treating hematologic malignancies, but can have toxic side-
effects due to binding healthy tissue. An anti-EGFR/anti-CD3
Probody TCB eliminated established EGFRC HT-29 colorectal
tumors in human T cell engrafted NSG mice, having potency
within 2- to 3-fold of an antibody-TCB, but gaining a >30-
fold increase in the maximum tolerated dose in cynomolgus
monkeys relative to the Ab-TCB. Again this demonstrates the
potential beneﬁt to safety as CytomX have noted limited leak-
age of the Probody therapeutic from the sites of cleavage
within tumors.
Dr. Desnoyers also commented that the masking of each
paratope required a speciﬁc peptide mask that can reduce afﬁn-
ity by up to 1000-fold, although, for example, a cetuximab Pro-
body therapeutic demonstrates a »30-fold reduction.
Immunogenicity hasn’t been studied widely, but in proof of
concept studies with a Probody variant of cetuximab, there was
no increase in the anti-Ig response.
Probody therapeutics redeﬁne the landscape of
antibody modalities in oncology
Andreas Pl€uckthun (University of Z€urich) addressed the
theme from an alternative angle in his lecture, presenting data
for designed ankyrin repeat protein (DARPin)-toxin fusions
whose selectivity was engineered by bioorthogonal veiling.
DARPins are a non-antibody class of small protein afﬁnity
reagents engineered from natural ankyrin repeat proteins, one
of the most common binding proteins in nature and responsi-
ble for diverse functions such as cell signaling and receptor
binding. The DARPins have favorable properties of high
potency, high stability, high afﬁnity, ﬂexible architecture and
ease of production that can be used singularly or in combina-
tion in 2 or more to bind multiple targets or epitopes. Examples
of clinical phase molecules are Abicipar, an anti-VEGF-A
DARPin for wet AMD entering Phase 3 and MP0250, an anti-
HGF and VEGF bispeciﬁc DARPin in Phase 1 clinical study for
solid tumor cancers and hematological malignancies (devel-
oped by Molecular Partners AG).
The DARPins are free from Cys and Met and can be
made Lys-free, thereby offering choices for coupling drugs,
such as monomethylauristatin F toxin and Pseudomonas
aeruginosa exotoxin A (ETA), through compatible biorthog-
onal click chemistry. However, reducing the toxicity caused
by target-independent uptake of such molecules fused to
biological drugs remains a challenge. Therefore, Pl€uckthun
and colleagues have developed methods to cloak DARPin-
ETA fusions to improve pharmacological properties using
site-speciﬁc addition of polyethylene glycol (PEG) moieties
using azide alkyne cycloaddition. PEG serves as a veil to
reduce immunogenicity, improve selectivity and improve
the half-life of the molecule. An anti-EpCAM DARPin
(Ec1) and a domain I-deleted variant of ETA (ETA00) was
developed as a prodrug and both linear and branched PEG
moieties were added at speciﬁc sites using a linker designed
to be susceptible to tumor-speciﬁc protease cleavage,
unmasking its full activity through loss of PEG. The native
REDLK sequence of the toxin was replaced with the canonical
eukaryotic ER-retention signal KDEL. Two key positions, one
within the catalytic domain and one close to the C-terminal
KDEL sequence of Ec1-ETA00 (Ec1-ETA00486Aha-AhaKDEL-
3C-PEG) were identiﬁed that lowered cytotoxicity 1000-fold
in EpCAM-positive tumor cells when both were PEGylated
with 20 kDa linear PEG. However, following proteolytic cleav-
age of the linker-PEG moiety, the molecule was fully potent.
The PEGylated Ec1-ETA00 was much better tolerated than
Ec1-ETA00, providing a longer circulation half-life (82 min
compared to 7.5 min for the unPEGylated format) and an
almost 10-fold increased area under the curve (AUC), follow-
ing systemic intravenous delivery.17
Intracellular delivery was also investigated using fusions
of EpCAM-targeting DARPins with the full-length pore-
forming protein of anthrax toxin, “protective antigen”
(N682A/D683A mutant), or the translocation domain of
ETA (252–412) and cargo DARPins. Interestingly, for the
anthrax toxin, the stability of the cargo had to be less than
the threshold thermodynamic stability for anthrax pores
due to the requirement for unfolding in retrograde translo-
cation. Therefore, a destabilized DARPin mutant carrying a
point mutation was necessary. Assays monitoring delivery
were developed that required biotinylation of an AviTagTM
sequence (carried on the cargo) by prokaryotic biotin ligase
(BirA) expressed in a FlpIn 293 EpCAM/BirA cell line or
MCF7 cells that transiently overexpress BirA. Studies using
the ETA domain and phosphorylated ERK-binding N2C
DARPin demonstrated efﬁcient uptake and high nM con-
centrations of delivered cargo, even saturating the pathway.
Importantly, the modular systems described in the presenta-
tion have the potential to overcome critical barriers for the
therapeutic use of toxins to modulate targets beyond the
reach of current biological drugs in a safe manner.18
Pareto optimal biotherapeutic deimmunization: P99
beta-lactamase as a case study for ADEPT fusion
partners
Antibody-targeted toxins and prodrug converting enzymes
can be powerful anticancer treatments, but therapeutic pro-
tein payloads present a risk of undesirable immunogenicity.
Karl Griswold (Thayer School of Engineering) described
experimental validation of integrated protein deimmuniza-
tion algorithms that deplete immunogenic T cell epitopes
while maintaining protein activity. The Pareto optimal
methods efﬁciently and accurately mapped the protein
design space, enabling aggressive molecular engineering that
balances the tradeoffs between immunogenic potential and
therapeutic function.
CRISPR libraries for functional genomics
David E. Root (Broad Institute of Harvard and MIT) dis-
cussed CRISPR, which has emerged as a powerful tool for
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genetic engineering and functional screens. Work by Prof.
Root and others have improved the design of CRISPR
libraries to achieve better gene perturbation efﬁcacy and
speciﬁcity using this technology.
Track B & C: New developments in antibody-drug
conjugates
Joost Melis
James S. Huston (Huston BioConsulting LLC) chaired the
Track B & C shared morning session, which focused on topics
related to ADC development.
Challenges associated with the development of
antibody drug conjugates
Paul Polakis (Genentech) discussed challenges associated
with the development of antibody drug conjugates. Target-
dependent toxicity, heterogenic target expression, target
shedding and ADC catabolism were discussed after a short
introduction of the multiple components of ADCs. Diver-
gent targeted drug-dependent toxicity of several ADC prod-
ucts were mentioned and showed that drug mechanism of
action determines target-dependent killing of normal cells;
while NaPi2b demonstrated high levels of expression in
normal lung tissue, toxicity was not associated with this tis-
sue in a clinical study of anti-NaPi2b-vc-MMAE. Secondly,
MSLN is highly expressed in the pleural lining of lung, yet
no adverse pleuritis events were seen in a Phase 1 study of
anti-MSLN-vc-MMAE. This was in contrast to previous
clinical study in which targeting MSLN with an immuno-
toxin resulted in ﬂorid pleuritis. Data was also presented
indicating that toxin-dependent efﬁcacy can vary under dif-
ferent circumstances. Xenograft studies using anti-CD22
ADCs armed with either PNU or MMAE efﬁcacious in a
BJAB model, but the PNU ADC remained efﬁcacious in the
model made resistant to the MMAE ADC. Targeting of
LGR5 in the normal intestine resulted in target-dependent
toxicity for PNU, but not for MMAE.
Next, results on the EDNRB target for melanoma treat-
ment were discussed. Separately administrating a MEK
inhibitor or ADC demonstrated only moderate efﬁcacy
responses, but the combining the 2 treatments showed an
enhanced effect in preclinical models. It was shown that
induction of EDNRB expression in response to MAKP
pathway inhibition (e.g., by a MEK inhibitor) increased the
availability of the target for an anti-EDNRB ADC. Mela-
noma patients in the anti-EDNRB-vc-MMAE clinical study
exhibited heterogeneous responses to treatment, suggesting
that varying levels of MAPK pathway activity could have
contributed to variable target expression, thus inﬂuencing
the responses to ADC treatment.
Decreased ADC efﬁcacy can be the result of various
mechanisms. One possibility is the presence of circulating
shed target antigen. This was discussed in the context of the
MUC16 ADC clinical study. The MUC16 extracellular
domain is shed as CA125, which can potentially interfere
with pharmacokinetics (PK) assays and can result in immune
complex formation. However, the CA125 expression levels
showed no relation to PK in patients. The lack of any PK
effect was consistent with analysis showing that clinically
high levels of CA125 are still proportionately very low rela-
tive to circulating levels of the MUC16 ADC. Finally, 3
examples were provided to illustrate a relationship between
rapid pharmacologic clearance of ADCs and increased toxic-
ity. An over-drugged antibody, a Fab fragment and a mutant
IgG with compromised binding to the neonatal Fc receptor
(FcRn), all cleared more rapidly than wild type IgGs and
produced greater toxicity and weaker efﬁcacy when adminis-
tered at equivalent drug levels. Thus, the rate of ADC catab-
olism or clearance can be inversely related to efﬁcacy and
directly related to toxicity.
Modeling aids design of antibody drug conjugates
Next topic highlighted the development of a mechanistic
tumor penetration model to guide ADC design, presented by
Bruce Gomes (Novartis). The goal of this project was to cre-
ate a modular mechanistic model for ADCs to aid in param-
eter design like afﬁnity, half-life, and payload properties. All
relevant processes are represented by physical properties,
and the aim is to make predictions before reagents are actu-
ally available to determine up-front risk and feasibility of
ADC projects. The model is ideally ﬂexible enough to be
used for different species, can be repurposed for many differ-
ent targets, and allows rapid answers to research questions. A
complete model of ADC takes into account a multitude of
parameters, such as ADC distribution, tumor penetration
and diffusion, receptor binding, internalization, recycling,
linker cleavage, cell sensitivity, peripheral vs. tumor killing,
tumor doubling and cell cycle dynamics and killing rate, plus
as much info that can be found speciﬁc to the target. The
presented model identiﬁed undesirable tumor properties that
can impair ADC tissue homogeneity and compromise ADC
success, and explored ADC design optimization scenarios to
counteract unfavorable intrinsic tumor tissue attributes. For
instance, the model demonstrated the profound impact of
cytotoxic payload release mechanisms and the role of
bystander killing effects on tumor shrinkage. Cell cycle
times, target receptor density and penetration or diffusion
from circulation to tumor cells play a role in efﬁcacy. Very
high afﬁnity binding or high receptor density can result in
the unbalanced distribution of the ADC to tumor cells,
mostly targeting the most proximal tumor cells to the capil-
lary and leaving the more distal tumor cells unbound. Tumor
mass shrinkage is also a function of target receptor kinetics
(e.g., recycling rate) and intrinsic tumor growth properties
(e.g., tumor doubling time). Tumor cells with high doubling
rates are most effective as targets since this will increase
ADC efﬁcacy. A next step in mechanistic modeling involved
therapeutic index modeling that has not been that successful
yet, since it is troublesome to correctly parameterize and
estimate characteristics of both tumor cells and normal tis-
sue. However, the current mechanistic model that was cre-
ated for ADC treatment allows optimization of properties of
all aspects of ADCs and ﬁts with time constraints of drug
discovery. It allows rapid hypothesis testing, and the model
is suitable to reparametrize to ﬁt different species.
626 M. PAUTHNER ET AL.
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 L
on
do
n]
 at
 07
:33
 24
 Ju
ne
 20
16
 
Building on the success of kadcyla: The next wave of
innovation in ADC technologies
John Lambert (ImmunoGen) then discussed the next inno-
vation wave in ADC technologies, building on the success
of Kadcyla. Ado-trastuzumab emtansine (T-DM1 or
Kadcyla) and the general challenges for a successful ADC
(tumor penetration, lysosomal activation, metabolites and
safety proﬁles) were brieﬂy discussed, followed by the may-
tansinoid ADC platform of ImmunoGen. Linker design was
a special focus in this segment, since the nature of the
linker determines tumor metabolites in vivo. The release
mechanism of a non-cleavable ADC is lysosomal degrada-
tion, but some targets recycle to the cell membrane thereby
avoiding the lysosome. Disulﬁde cleavage of linkers in
endosomal compartments enables release of neutral toxin
molecules within the cell that are also able to kill nearby
cells via the so-called bystander effect. Differences between
various linkers were highlighted by characteristics of
SMCC-DM1 (non-cleavable), SPP-DM1 and SPDB-DM4
(both cleavable). Implementing the hydrophilic sulfo-SPDB
linker further enhanced DM4 activity in vitro and in vivo
toward MDRC cells, thereby increasing the potency of the
ADC. Clinical efﬁcacy overviews of 3 maytansinoid ADCs
were presented, among which was mirvetuximab soravtan-
sine (anti-folate receptor-sulfo-SPDB-DM4). For this drug,
bystander killing is one mechanism that likely contributes
to clinical proﬁle of the ADC.
The second half of the presentation focused on payload
innovation targeting DNA. Some tumor types appear insen-
sitive to tubulin inhibitors, so DNA-acting toxins could cre-
ate new opportunities for ADCs to addressing these
cancers, but the real challenge using these toxins is to create
a good therapeutic window. The IGN (indolino-benzodiaze-
pine backbone) payload is an ultra-potent DNA-acting pay-
load that is more potent than PBD SJG-136, exempliﬁed by
data showing improved potency on B cell cancer cells and a
colon cancer cell line using IGN vs SJG136 head-to-head.
The introduction of a phenyl ring further increased potency
of the IGN payload, and in vivo a potent dose-responsive
anti-tumor activity was established. However, the toxicity
proﬁle of this product was less favorable demonstrating
delayed or prolonged toxicity, possibly associated with the
mechanism of potent DNA crosslinking by the di-imine. As
a next step, a DNA alkylating mechanism of action (mono-
imine) was designed to prevent crosslinking on DNA
strands. Although this decreased the potency by 2-to-3-fold,
it resulted in an acceptable toxicity proﬁle and an overall
improved therapeutic index. Linker choice can further alter
the toxicity proﬁle in vivo in mice. Introducing a disulﬁde
linker for this alkylating format enhanced potency again
and further improved the safety proﬁle. IMGN779 (target-
ing CD33) was mentioned as an example of a promising
IGN-based ADC. Adding a cleavable sulfo-SPDB linker
resulted in an ADC with average DAR of 3, and picomolar
potency was achieved for several acute myeloid leukemia
(AML) cell lines. Robust anti-tumor activity was achieved
in AML xenograft models at a single 0.5 mg/kg (antibody)
dose. Improved activity of IMGN779 against primary
patient cells relative to AVE9633 (maytansinoid) was also
demonstrated. IMGN779 was well-tolerated in CD-1 mice,
with no observed hepatotoxicity or prolonged toxicity
(40 mg/kg single dose). An IND for this drug was accepted
recently, and a ﬁrst-in-human trial is expected to begin
before the end of Q2 2016.
Innovation continues on the IGN ADC platform, with
data presented on 2 novel compounds, “D1” (disulﬁde link-
age) and “P1” (cleavable peptide L-Ala-L-Ala), that demon-
strated higher in vitro potency and in vivo efﬁcacy relative
to the IGN utilized in IMGN779, plus a maintained or
increased therapeutic window in mouse models.
Antibody drug conjugates: Advancements in drug,
linker and conjugation technologies
Peter Senter (Seattle Genetics) discussed advancements in
drug, linker and conjugation technologies Hodgkin Lym-
phoma (HL) and systemic anaplastic large cell lymphoma
(sALCL) are CD30 positive diseases with unmet needs
with»9000 and »5000 per year in the US, respectively. The
chimeric antibody cAC10 targets CD30 and is rapidly inter-
nalized upon binding, which makes it a suitable candidate
antibody to be used in an ADC format. Brentuximab vedo-
tin consists of the cAC10-directed antibody and the micro-
tubulin inhibitor MMAE linked via cathepsin cleavable
valine-citrulline linker. A clinical efﬁcacy comparison of the
anti-CD30 ADC brentuximab vedotin and the unconjugated
anti-CD30 antibody demonstrated 75% vs 0% OR, respec-
tively, clearly favoring the ADC approach. The toxicity pro-
ﬁle of anti-CD30 ADC was discussed brieﬂy, with
neutropenia and peripheral neuropathy as the main
observed toxicities. This can be linked to the fact that nerve
cells are more sensitive to microtubulin inhibition drugs
than other cells. Next, data on the stability of the ADC was
presented. The vc-MMAE product exhibited a half-life of
approximately 1 week in mice and monkeys. It was sug-
gested that MMAE in serum is partly responsible for the
demonstrated toxicity proﬁle.
To improve the toxicity proﬁle, efforts were made to
avoid the reversible fragmentation reaction of maleimide
taking place, which results in detachment of the toxin from
the antibody and thereby causing unwanted side effects.
Avoiding this reaction resulted in a more stabilized ADC,
showing enhanced efﬁcacy and an improved toxicity proﬁle.
As an example a decrease in neutropenia in rats was shown.
Another improvement was made by reducing the hydropho-
bicity of the ADC product, which could be an underlying
cause of accelerated clearance. The drug-linker was engi-
neered such that unnecessary hydrophobic elements were
eliminated, which resulted in an improved PK proﬁle and
increased therapeutic window. Implementing a more hydro-
philic MMAE product with a DAR of 8 resulted in a higher
efﬁcacy than the DAR 4 variant, which was the opposite for
the hydrophobic MMAE product. Further improvements
were made by reducing the heterogeneity of ADCs. Initial
ADC products consisted of a mixture of species with a 0-2-
4-6-8 DAR range. The average DAR of 4 is reproducible
and high yielding, but more homogeneous products are
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desirable for future ADCs. To achieve this, initial attempts
to modify the glycan structure for conjugation purposes
resulted in active, but unacceptable heterogeneous products.
Integrated engineered cysteine residues that are buried in
the cavity of the Fc portion resulted in more homogeneous
and stable ADCs. This novel technology is now used for
the new drug SGN-33A (CD33-PBD ADC) targeting acute
lymphoblastic leukemia. SGN-33A demonstrated an
improved IC50 over gemtuzumab ozogamicin (Mylotarg)
and ongoing results from the Phase 1 clinical study were
presented. Overall, the results presented demonstrated new
technological and application advancements for ADC
technology.
Calicheamicin antibody-drug conjugates and beyond
Puja Sapra (Pﬁzer) took the stage to discuss calicheamicin
ADCs and other novel payload agents.
Novel ADC against tissue factor for treatment of solid
tumors
Next, Bart de Goeij (Genmab) presented a novel ADC product
for the treatment of solid tumors targeting tissue factor (TF)
and highlighting promising results from preclinical and ﬁrst-
in-human studies. TF is present in sub-endothelial cells in the
blood vessel wall and upon vascular damage proteins in the
blood stream that, upon binding to TF, can initiate the blood
coagulation cascade to achieve closure of the ruptured blood
vessel. TF expression can also result in PAR-2 activation in a
normal situation. Aberrant expression is found in many tumor
types (shown for e.g., prostate, cervical, bladder, and ovarian
cancer). The critical steps for possible development of TF as an
ADC format were investigated. Firstly, expression patterns and
distribution of the target were assessed. Confocal microscopy
analyses in non-stimulated tumor cells indicated that a large
portion of TF is present in intracellular compartments (includ-
ing lysosomes), indicating a high turnover of TF on tumor cells.
This was in contrary to targets such as HER2 and EGFR, which
are predominantly present on the plasma membrane. Flow
cytometry analyses demonstrated that TF on plasma membrane
is able to internalize without an antibody or a ligand being
present. Antibody-induced down-modulation of surface-
expressing TF was also demonstrated, which was not seen for
the targets HER2 and EGFR. Secondly, the internalization rate
of TF was assessed for the TF-011 antibody. Compared to
HER2 and EGFR antibodies, TF-011 showed very rapid inter-
nalization and high levels of lysosomal trafﬁcking.19
These results indicated TF is an interesting target for an
ADC approach and next, a TF-vc-MMAE ADC was developed
and tested for efﬁcacy.20 Xenograft data on HPAF-II (positive
for TF expression) and PANC-1 (negative for TF expression)
models were discussed and efﬁcacy was demonstrated for the
TF-expressing HPAF-II model. Further anti-tumor activity was
shown in PDX models for lung adenocarcinoma (TF expression
in 75% of cells) and cervical squamous cell carcinoma (TF
expression in 25–50% of cells), also after paclitaxel treatment.
Data from the cervical cancer PDX model implied a possible
bystander effect of the ADC. The ability of TF-vc-MMAE to
induce bystander kill was later conﬁrmed by comparing
bystander cell kill effects using MMAE versus MMAF.
Safety proﬁling in cynomolgus monkeys determined that
anti-TF dosed up to 100 mg/kg had no effect on coagulant
activities of TF; no differences on functional bleeding time in a
Surgicutt assay, prothrombin time or activated partial throm-
boplastin time were exhibited when compared to the normal
situation. IHC analyses of TF expression in healthy human and
cynomolgus tissue indicated a wide-spread expression of TF. A
toxicity proﬁle was established by administering HuMax-TF-
ADC once every 21 d (1, 3, and 5 mg/kg dose groups). Some
skin reactions were apparent, which were severe at the highest
dose but reversible. A drop in neutrophils was noted at all
tested doses, and at 5 mg/kg the red blood cell count was
slightly reduced. Overall a narrow toxicity proﬁle was demon-
strated with skin, bone marrow and testes as the only target
organs. The GEN701 ﬁrst-in-human dose-escalation study on
locally advanced and/or metastatic solid tumors known to
express TF demonstrated promising results. 24 patients were
dosed up to 2.2 mg/kg with some dose-limiting toxicity appar-
ent. A 1.8 mg/kg dose was well-tolerated, and an intermediate
2 mg/kg dose is now being tested. This study demonstrated
encouraging anti-tumor activity in this heavily pre-treated
patient population; 10 patients showed a stable disease response
and 1 patient a partial response.
Track A: Bispeciﬁc antibodies: New technologies and
applications
Matthias Pauthner
Paul Carter (Genentech) chaired the afternoon session of
Track A, which focused on bispeciﬁc antibodies.
Optimization and application of Fc-containing
bispeciﬁc antibodies
John Desjarlais (Xencor) presented a plug-and-play bispeciﬁc
platform for generating bsAb with long serum half-life. Xencor
has developed a new platform for long-lived and easy to manu-
facture bispeciﬁc antibodies. This platform was applied to rap-
idly produce CD3 bispeciﬁc antibodies targeting CD123 for
AML, CD20 for B cell malignancies, and CD38 for multiple
myeloma. Each antibody is shown to be potently active in non-
human primate studies, and manufacturing at GMP scale is
straightforward with yields greater than 2 g/L. Application to
multiple formats and target combinations was also discussed.
Facile generation of common light chain bispeciﬁc
antibodies
Eric Krauland (Adimab) surveyed Adimab’s technology for
generating common light-chain (cLC) bispeciﬁc antibodies
(bsAbs). BsAbs based on the IgG format must contend with
dimerization events between the heavy chains (HCs) and light
chains (LCs). Most technologies used to solve this so-called
light-chain pairing problem in a single host cell production set-
ting (e.g., knobs-in-holes, domain swaps, orthogonal Fab inter-
faces or electrostatic steering) come with the potential
disadvantage of introducing mutations into otherwise human
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sequences. To circumvent this problem, cLCs in both Fab arms
present an elegant solution.
Dr. Krauland opened his talk by underlining the theoretical
feasibility of cLC discovery for a wide array of targets. Analysis
of over 100 antibody-antigen co-crystal structures revealed
only 30% LC CDR contributions to binding energy, opposed to
70% contributed by HCs. Further, HC CDRs are more mutated
than LC CDRs, in fact CDR L3s often deviate very little from
their germline sequences, which is also reﬂected in the pool of
USAN/WHO-INN designated mAbs: as of 2014, there were 14
pairs of mAbs against unrelated targets, but identical CDR L3
sequences.
Dr. Krauland then explained the details of Adimab’s cLC
discovery platform, which is centered on full IgG libraries with
separate genetic elements for HCs and LCs. This feature greatly
expedites the library generation for HCs with restricted LC
diversity, both if one target mAb is already known (104-107 HC
diversity, 1 week) or for de novo identiﬁcation of 2 HC speciﬁc-
ities with a predetermined restricted set of cLCs (1010 HC
diversity, 1–3 months). Further, known or discovered HC spe-
ciﬁcities can be shufﬂed into small (<10 ) cLC libraries for
comparative identiﬁcation of LCs that work effectively with all
desired HCs. A subsequent single round of afﬁnity maturation
yielded nanomolar IgG binders in this scenario, which are
ready for immediate bsAb formatting.
In the last section of his talk, Dr. Krauland outlined
Adimab’s in-house puriﬁcation approach for bsAbs. Consis-
tent with Adimab’s overall strategy of keeping mAb constant
regions unaltered, the company opted for a puriﬁcation strat-
egy to enrich correctly paired bsAbs rather than introducing
heterodimerization mutations in the Fc region. The puriﬁca-
tion starts with a Protein A (MAb Select Sure) enrichment,
followed by separation of the bsAb species based on intrinsic
VH charge variation using ion-exchange chromatography
(Mono S/Mono Q). Starting with a wide linear elution gradi-
ent of pH4-11, speciﬁcity and yield were strongly increased by
closing in on the desired elution pH range. This method was
used to purify bsAbs in which the isoelectric point of each VH
varied by less than one-half unit, and with sensitivity down to
a single positive to negative charge inversion. Dr. Krauland
closed with a case study of an Adimab produced EGFR x
HER2 cLC bsAb, which was enriched to >99% purity,
retained picomolar afﬁnity to both targets and passed ELISA/
FACS based dual-binding characterizations.
Insights into the molecular basis of a bispeciﬁc
antibody’s target selectivity
As discussed by Yariv Mazor (MedImmune), dual targeting is
thought to enhance biological efﬁcacy, limit escape mecha-
nisms, and increase target selectivity via a strong avidity effect
mediated by concurrent binding to both antigens on the surface
of the same cell. However, factors that regulate the extent of
target selectivity are not well understood. It was shown that
dual targeting alone is not sufﬁcient to promote efﬁcient target
selectivity. Substantial roles played by the afﬁnity of the indi-
vidual arms, overall avidity and valence were shown. These
ﬁndings have important implications on the development of
clinically relevant bsAbs.
Efﬁcient production of bispeciﬁc IgG in a single host
cell
Yiyuan Yin (Genentech) discussed novel protein-engineering
based solutions to the light-chain pairing problem, which
severely reduces yield in single host cell bsAb production sys-
tems. Assuming correct HC pairing, co-expression of light
chains that lack intrinsic binding preferences to their cognate
HC theoretically only yield 25% correctly paired bsAbs, thereby
greatly increasing production cost. Other solutions to this prob-
lem include the use of common LCs and domain-swapped Fab
arms, while engineering-based approaches utilize knob-in-hole
(KIH), electrostatic steering, modiﬁed disulﬁde bonds or com-
plete orthogonal interface design to create speciﬁcally interact-
ing HC/LC pairs, thus increasing bsAb production yield.
Dr. Yin started out by introducing the test system for her
engineered design, an anti-HER2/CD3 bsAb. To generate HC/
LC paring speciﬁcity, both mutations in the CH1/CL interface
(1 knob/1 hole, 2 knobs/2 holes - up to 10 residues in both
chains altered) as well as engineered charge pairs in the VH/VL
interface (e.g., Q39 E/Q38 K) were designed and optimized
using computation heavy Rosetta modeling. The top hits were
than expressed, Protein A or G puriﬁed and tested for yield, sta-
bility and bsAb functionality using sandwich-ELISAs.
In summary, Dr. Yin’s group was able to identify multiple
CH1/CL as well as VH/VL interface mutations that were transfer-
able between different bsAb constructs and greatly increased
yield, without deteriorating binding characteristics. While wild-
type bsAb yield is dependent on the actual speciﬁcities - rang-
ing from »25% (HER2/CD3) to »90% - the discovered muta-
tions were able to strongly increase yield from 25% to >90 %
(HER2/CD3), and for other bsAb speciﬁcities up to 100%,
thereby providing a great solution for cost-effective single host
cell bsAb production. Possible disadvantages to engineering-
heavy bsAb designs may include reduced serum half-life due to
anti-bsAb immune reactions; however, this remains to be clini-
cally investigated.
Nanobodies as a versatile and clinically validated
approach for bispeciﬁc development
Antonin de Fougerolles (Ablynx) commenced his talk by
introducing Ablynx’s proprietary Nanobody (Nanobody is a
registered trademark of Ablynx NV) technology. Nanobodies
are derived from the antigen binding VHH domains of heavy
chain only antibodies found in llamas and other camelids.
These very small 12–15 kDa binding domains offer many
advantages, including they 1) can be easily stringed together
for increased functionality or binding avidity, 2) are able to
bind challenging targets like GPCRs and ion channels, and 3)
can be produced robustly and cost effectively at high yield in
microbial cells due to absence of canonical N-linked glycosyla-
tion sites. Ablynx’s discovery process starts by either immu-
nizing llamas with antigens and retrieving the VHH domains
or starting from proprietary Nanobody phage libraries. Upon
selection and screening, single VHH domain Nanobodies, typi-
cally in the low nM and pM binding range, are isolated to the
desired target of interest. Subsequently, different Nanobodies
can be rapidly formatted into multi-valent or multi-speciﬁc
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constructs as needed, produced, and evaluated in pre-clinical
or clinical tests.
The extraordinary small size and robustness of Nanobodies
allow for uniquely modular combinations of identical or heter-
ologous Nanobodies with short GS-linkers. For example, by
adding an anti-human serum albumin-binding Nanobody to a
string, the serum half-life in humans can be dramatically
increased from »2–18 hrs to 10–20 d. However, the very short
serum half-life of unmodiﬁed Nanobodies can also be exploited
if rapid renal clearance is desired, which is e.g., the case for
caplacizumab, Ablynx’s in-house Phase 3 clinical candidate
designated for the treatment of acquired thrombotic thrombo-
cytopenic purpura.
The modular stringing together of Nanobodies also enables
the generation of multi-valent, bi-paratopic and multi-speciﬁc
conjugates. For example, the tri-valent RSV binding Nanobody,
ALX-0171, shows increased potency, with5-fold more clinical
isolates neutralized below the lower limit of detection than with
palivizumab. Another interesting application is the generation
of bi-paratopic conjugates, in which 2 non-competing Nano-
bodies binding the same antigen are linked together. In one
case-study, an anti-IL23 bi-paratopic Nanobody showed a 25-
fold increase in in vivo biological activity over bi-valent Nano-
bodies or benchmark mAbs. Finally, the Nanobody platform
also allows the facile generation of bi-, tri- or multi-speciﬁc
conjugates. In addition to common oncology BsAb applica-
tions, Dr. de Fougerolles presented an impressive 160-fold
increase in HIV neutralization potency of a CXCR4/CD4 bi-
speciﬁc Nanobody over an equal mixture of the 2 mono-spe-
ciﬁc Nanobodies. Other applications for the technology include
increased cell targeting speciﬁcity for immuno-oncology set-
ting, in which 2 heterologous Nanobodies identify and bind the
correct target cell while additional linked Nanobodies can carry
out effector functions, like recruiting T cells (anti-CD3).
Bispeciﬁc TCR-based reagents for targeted cancer
immunotherapy
Bent Jakobsen (Immunocore) discussed ImmTACs, which are
bispeciﬁc reagents that target tumors via a soluble monoclonal
TCR with exceptionally high sensitivity and speciﬁcity and
redirect host polyclonal T cells via an anti-CD3 antibody frag-
ment. Emerging data from the ﬁrst ImmTAC to enter Phase 1/
2a clinical trials demonstrated durable partial responses in
patients with advanced melanoma.
Track B: Antibody therapeutics for non-cancer
indications
Joost Bakker
Trudi Veldman (AbbVie Bioresearch Center) chaired the
afternoon’s Track B session.
ESBA1008 (RTH258, broculizumab), a highly stable
scFv for treatment of age-related macular
degeneration
ScFv have potential advantages, such as better penetration,
durability, and fast clearance, which lead to better safety.
However, they are known to be highly unstable and tend to
aggregate. Patrik Maurer (ESBATech, a Novartis company)
and colleagues solved this problem by use of highly stable
human frameworks for grafting of CDRs. Broculizumab is an
anti-VEGF scFv with rabbit CDRs. The outer loop looks differ-
ent though no decrease in binding afﬁnity was found. Broculi-
zumab is thermo-stable, and high concentrations can be used
for application in the eye. Broculizumab is stable at 4C for at
least one year. Competitors in the ﬁeld are bevacizumab, ranibi-
zumab and aﬂibercept.
In in vitro experiments, tissue penetration was higher with
broculizumab than with competitors, and no toxicity was
observed in animals. Lucentis (ranibizumab) works well in
treatment of age-related macular degeneration, but has to be
injected monthly. Treatment with broculizumab might lead to
longer duration of efﬁcacy. In a Phase 2 study, efﬁcacy of bro-
culizumab was measured using optical coherence tomography
(OCT), which measures leakage and changes in the thickness
of the retina. Compared to ranibizumab, broculizumab leads to
30-day prolongation of treatment effect. Compared to aﬂiber-
cept, the same improvement in sharp sight and reduction of
retinal thickness were observed, but with a 3-monthly vs. a
monthly injection interval.
A Phase 3 clinical study is currently ongoing and is expected
to be completed in 2018. This trial consists of a head-to-head
comparison against aﬂibercept and different dosing schedules.
The ESBATech technology for stabilizing scFv molecules
appears to work well. Furthermore, no increase in ADA devel-
opment was observed. This is an important observation since
the eye is not completely protected against injection of foreign
proteins.
Therapeutic anti-citrullinated protein antibodies
reduce inﬂammation by inhibition of NETosis
Conversion of peptidyL-arginine into peptidyl-citrulline (citrul-
lination) leads to altered protein refolding and loss of function
of proteins. Proteins can become autoantigenic after such con-
version. A strong link to arthritis in rheumatic arthritis (RA)
patients and anti-citrullinated antibodies exists.
Neutrophil extracellular traps (NETs) are associated with a
unique form of cell death, distinct from apoptosis or necrosis,
whereby invading microbes are trapped and killed. Neutrophil
extracellular traps can contribute to autoimmunity by exposing
autoantigens, inducing cytokine and chemokine production,
and activating the complement system. Therapeutic anti-citrul-
linated protein antibodies (tACPA) have been identiﬁed from
RA patients and bind speciﬁcally to the conserved citrullinated
N-terminus of histones H2A and H4. tACPA binding of these
targets in the early stages of NETosis blocks NET formation
and thus blocks autoantigen exposure.
Jos Raats (ModiQuest) discussed the company’s lead anti-
body, which is a humanized IgG1 that binds to histones H2A
and H4. Different assays for NETosis inhibition have been
used, in which MPO/NE activity and immunoﬂuorescence
staining showed that NETs formation is strongly reduced after
addition of tACPA, but not after adding an isotype control
antibody. NETs have been detected in RA joints where they
add to the severity of the disease. tACPA treatment was
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investigated in 2 different RA mouse models. RA inﬂammation
was completely prevented or strongly reduced by tACPA in an
early treatment model, whereas, in a therapeutic model, tACPA
blocked the increase in inﬂammation. Moreover, combination
therapy with tACPA and dexamethasone demonstrated that
inﬂammation could be reversed completely. With dexametha-
sone only treatment, severe relapses occurred quickly within a
few days after stopping dexamethasone treatment, whereas, in
tACPA treated animals, after stopping dexamethasone treat-
ment, relapses occurred much later and inﬂammation levels
were much milder.
Histology data demonstrated that tACPA treatment pro-
tected the animals against massive cartilage and bone destruc-
tion. NETs are also linked to ﬁbrosis, inﬂammatory bowel
disease, acute lung injury, and cystic ﬁbrosis. Prophylactic
tACPA treatment in a pulmonary ﬁbrosis animal model
showed protection against ﬁbrosis in the lung. Clinical proof of
concept is expected in 2018/2019.
Predictive biomarkers for response to therapy in IBD
A challenge in drug development for irritable bowel diseases
has been identifying patients likely to respond to novel thera-
pies. Mary Keir (Genentech) discussed results from a Phase 2
study of etrolizumab, a humanized monoclonal antibody that
selectively binds the b7 subunit of the heterodimeric integrins
a4b7 and aEb7, showed clinical beneﬁt in moderate-to-
severely active ulcerative colitis. Post-hoc analysis showed
enrichment of clinical remission in aE-high patients, suggest-
ing that baseline aE levels may be predictive of etrolizumab
response.
Targeting therapeutic and regenerative biomedicine
speciﬁcally to arthritic joints
As discussed by Ahuva Nissim (Queen Mary University), exe-
cuted studies have focused on developing a panel of human
antibodies that bind speciﬁcally to collagen type II post-transla-
tionally modiﬁed by reactive oxidants (ROS) present in the
arthritic joints. ROS are known to play an important role in the
disease, and different forms and subforms are present during
inﬂammation. The aim has been to validate their potential tar-
geting for immunotherapy and early diagnosis of arthritis.
Importantly, the goal of these new immunotherapeutics is to
reduce side effects, increase the response rate, and treat early
stage arthritis.
Collagen type II (CII) is a major component of articular car-
tilage and thus a prominent target of ROS. Antibodies against
CII modiﬁed by ROS (ROS-CII) were generated and the lead
clone has been shown to bind to all forms of ROS-CII (1–11E),
human RA cartilage and osteoarthritis (OA) cartilage. Further-
more, the selected clone also binds to cartilage from mice mod-
els of arthritis.
Interestingly, fusion of 1–11E clone to etanercept via a
matrix metalloproteinase-cleavable peptide linker will result in
release of etanercept at the inﬂamed site, which could locally
inhibit TNF-induced inﬂammation. Indeed, 1–11E fused to eta-
nercept signiﬁcantly reduced inﬂammation in arthritic mice, as
compared with etanercept alone or etanercept fused to an
irrelevant antibody. Also, fusion of 1–11E with viral interleukin
(IL)-10 restricted biological activity of viral IL-10 after it has
been released from the antibody following matrix metallopro-
teinase cleavage and thus might reduce inﬂammation explicitly
in the arthritic joints. Indeed, viral IL-10-fused protein induced
inhibition of inﬂammation in mice with inﬂammatory arthritis;
and a reduction in ROS in inﬂamed knees was observed. In
addition, the viral IL-10-fusion protein was able to reduce pro-
inﬂammatory cytokines. The drug can be administered system-
ically, but the drug is only active locally, at target sites.
There is an unmet need for the development of diagnostic
tools for early OA. To investigate whether the selected clone
could be used for this purpose, an OA mouse model with desta-
bilization of the medial meniscus (DMM) was used. Histology
data demonstrated staining of OA cartilage ahead of evident
cartilage damage. The clone can therefore also be used to detect
early OA even before evident cartilage damage. Retention of
the clone was found to be 4–8 weeks after surgery. Antibody
was found only locally in the DMM joints, and not in other
areas. This is due to speciﬁc binding to arthritic cartilage, as
has been observed with histology.
In conclusion, this strategy may potentially have a signiﬁ-
cant effect on the treatment efﬁcacy and modality for RA. In
addition, the selected clones may be developed as an imaging
biomarker for early OA diagnosis. Since the antibodies cross-
react with small animal tissue, this may facilitate development
of disease modifying osteoarthritis drugs.
Bispeciﬁc FynomAbs unlock new biology
Ulrich Wuellner (Covagen) discussed the company’s develop-
ment of bispeciﬁc FynomAbs by fusing its Fynomer binding
proteins to antibodies, resulting in multi-speciﬁc therapeutics
with novel modes-of-action and enhanced efﬁcacy. FynomAbs
have optimal biophysical and pharmacokinetic properties,
making them attractive as drug candidates. Here they presented
the discovery and development of COVA322, a clinical-stage
bispeciﬁc TNF/IL-17A inhibitor for the treatment of inﬂamma-
tory diseases. Dual cytokine inhibition holds great promise to
substantially improve current therapies.
ABT-122, an Anti-TNF/IL-17 dual variable domain
immunoglobulin (DVD-Ig), mechanisms of translation:
Bench to bedside and back again
Chung-Ming Hsieh (AbbVie) discussed ABT-122, an anti-
TNF/IL-17 DVD-Ig that is currently in Phase 2 trials for rheu-
matoid and psoriatic arthritis. To better understand its mecha-
nisms of action and identify potential biomarkers, gene array
analysis was performed in a mouse arthritis model followed by
evaluation of protein expression in healthy volunteers after a
single dose of ABT-122.
In vitro, TNF and IL-17 synergistically upregulate synthesis
of chemokines, cytokines, and MMP. Combined treatment of
RA mice with anti-TNF and anti-IL-17 results in superior effec-
tivity on RA. We identiﬁed multiple novel fully human anti-
bodies to IL-17 by mRNA display technology in vitro. From a
dsDNA antibody library, an antibody mRNA library was gener-
ated. Using in vitro translation, oligo dT and FLAG
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puriﬁcations an mRNA-scFv library was developed. IL-17 anti-
gen was subsequently used for antibody selection. Yeast surface
display was used for antibody discovery and engineering. After
IL-17 antibodies were afﬁnity-matured, DVD Ig molecules
were constructed. Afﬁnity of TNF and IL-17 was measured to
be in the 10 to 50 pM range respectively. The half-life of the
construct is approximately 14 d in rats.
ABT-122 was investigated for potential use as a biomarker.
In an ascending dose study in volunteers, no clinically adverse
events were observed, after biweekly subcutaneous injections.
Furthermore, ABT-122 fully neutralized TNF and IL-17 in a
potency assay, as measured by IL-6 production. Neutralizing
activity was present up to 3 weeks after administration to vol-
unteers, and the drug was well tolerated.
Next, it was investigated if ABT-122 affects chemokines, and
if these could be used as biomarkers. ABT-122 modulates
CXCL10 and CCL23, which are responsible for recruitment of
immune cells to the site of inﬂammation. The effects of ABT-
122 on these chemokine receptors were assessed using blood
samples from volunteers. Seven days after injection, a reduction
in CXCR4 and increase in CXCR 5 was observed. The func-
tional response of immune cells was also investigated and dem-
onstrated a decrease in gm-CSF response.
Track C: Site speciﬁc conjugations, novel chemistries
and payloads
Joost Melis
John Lambert (ImmunoGen) chaired the afternoon session
of Track C, which focused on site-speciﬁc conjugations, novel
chemistries, and payloads for ADCs.
Site-speciﬁc antibody-drug conjugates built on a
selenocysteine interface
The ﬁrst speaker, Christoph Rader (The Scripps Research
Institute), presented data on site-speciﬁc ADCs built on a sele-
nocysteine interface. One of the possibilities to improve an
ADC is incorporating site-speciﬁc conjugation instead of using
random drug conjugation. This can be achieved by making use
of natural or unnatural amino acids via chemical or enzymatic
conjugation. Selenocysteine (Sec) is the 21st natural amino acid,
is analogous to cysteine and serine, but has a selenium-contain-
ing selenol group in place of the sulfur-containing thiol group
when compared to cysteine. Sec is larger, more nucleophilic
and has a lower reduction potential in comparison to cysteine
(pKa 5.2 vs 8.3, respectively). Sec is co-translationally incorpo-
rated into proteins by recoding the UGA codon. Sec insertion
in eukaryotes requires the presence of the Sec insertion
machinery and a Sec insertion sequence (SECIS) element. A
method was developed for mammalian cell expression of the
human IgG1-derived Fc protein with a C-terminal Sec residue
by introducing an engineered SECIS element into an expression
cassette. This genetically engineered Fc protein displays a
unique chemical reactivity that enables selective conjugation to
a variable small synthetic molecule at the Sec interface. The
platform allows generation of recombinant IgG, Fab, scFv, and
IgM with a C-terminal Sec residue, which makes it possible to
develop ADCs with a DAR of 1. Sec incorporation is not
complete, only 1 in 5 products incorporate a selenocysteine, the
other 4 contain stop codons. Still a laboratory-scale production
of 4 mg/L is feasible. Selenomabs allow selective conjugation
for several formats, although stability issues arose when using
maleimide. Using iodoacetamide solved this stability issue.
MMAF derivatives can be linked using iodoacetamide, which
results in an average DAR of 0.6. This limited DAR still demon-
strated efﬁcacy as was shown testing an anti-HER2 ADC in
HER2-positive and -negative cell lines. In vivo target-directed
killing of the anti-HER2 ADC was also established in a KPL-4
orthotopic xenograft nude mouse model at 1 and 3 mg/kg.
Additionally, an anti-CD138 ADC exhibited in vitro efﬁcacy in
U266 and H929 cell lines and in vivo target-directed kill in an
U266 systemic xenograft mouse model. To improve the low
DAR, Sec was moved upstream into a CH3 position that
required Sec incorporation into both heavy chains for func-
tional selenomab assembly. HIC analysis conﬁrmed a DAR of 2
and yield reached 2 mg/L. The technology can also be com-
bined with the Thiomab platform, resulting in a thio-seleno-
mab dual warhead strategy. Firstly, Sec-conjugation occurs
under pH 5.2, followed by Cys-conjugation at pH 7.4.
Hapten-directed spontaneous disulﬁde shufﬂing: A
universal technology for site-directed covalent
coupling of payloads to antibodies
Next, Eike Hoffmann (Roche) presented a lecture entitled hap-
ten-directed spontaneous disulﬁde shufﬂing: a universal tech-
nology for site-directed covalent coupling of payloads to
antibodies. Individual analyses of known structures of digoxige-
nin and ﬂuorescein binding antibodies and a new structure of a
biotin-binder revealed a “universal” coupling position in prox-
imity to binding pockets, but without contributing to hapten
interactions. Hapten-binding antibodies with an accessible cys-
teine in proximity to the binding pocket were designed to cova-
lently attach payloads to the antibody. Payloads that carry a
free thiol are positioned on the antibody and covalently linked
to it via disulﬁdes by spontaneous redox shufﬂing. Attachment
at the universal position works with different haptens, antibod-
ies, and payloads and can be achieved by 15 minute incubation
of the antibody and the payload in equimolar ratios. Applica-
tions include modulation of pharmacokinetics of small com-
pounds as well as payload linkage to targeting vehicles in a
reduction-releasable manner.
Antibody pyrrolobenzodiazepine conjugates
Philip Howard (Medimmune/Spirogen) presented work on
antibody pyrrolobenzodiazepine conjugates (APCs). Several
APCs are currently undergoing clinical investigation. Seattle
Genetics is developing an APC targeting CD33 for treatment of
AML, plus an APC targeting CD70 in NHL/RCC. StemCentrx
is using an APC directed at DLL3 in SCLC and CisR in ovarian
cancer. Pyrrolobenzodiazepine (PBD) dimers are sequence-
selective DNA minor-groove binding crosslinking agents that
block replication and result in cell death, which was veriﬁed
here by results of an adapted Comet-assay. PBDs are extremely
potent (picomolar range) and are not cross resistant with cis-
platin, making them clinically interesting payload agents. The
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structure-activity relationships of PBD were discussed. For
example, the sugar moiety and electron donators enhance activ-
ity and bulky substituents can reduce or abolish activity of a
PBD. The PBD payloads tesirine and talirine were highlighted
and exemplifying efﬁcacy and safety data was presented. The
HER2-SG3249 APC treatment in a NCI N87 gastric carcinoma
xenograft model resulted in complete tumor regression at a
dose of 1 mg/kg. Promising tolerability data demonstrated no
delayed weight loss in mice yet (up to 78 days). The APC was
compared to T-DM1 in a BT474 model and APC treatment at
1 mg/kg showed complete tumor regression thereby outper-
forming T-DM1 at 1 mg/kg. Efﬁcacy was also demonstrated in
low HER2-expressing models such as the JIMT-1 model, again
showing complete tumor regression with no delayed weight
loss in the animals at a 1 mg/kg dose. Antibodies directed at
CD25 (component of IL2 receptor - IL2Ra) as a target of hema-
tological malignancies using a PBD payload (also known as
ADCT-301) showed good in vitro and in vivo activity. For
example, complete tumor regression was established at a
0.5 mg/kg dose in a Karpas 299 Anaplastic large cell lymphoma
in vivo model, thereby outperforming brentuximab vedotin
(Adcetris).
Subsequently, the collaboration with StemCentrx in small
cell lung cancer (SCLC) and large cell neuro-endocrine carci-
noma (LCNEC) was discussed. Data of the APC rovalpituzu-
mab tesirine (SG3249 linker with SG3199 PBD dimer)
targeting DLL3 was presented. DLL3 expression in lung tissue
and several lung cancers was shown and in vivo activity
appeared to correlate with DLL3 expression. In vivo data dis-
cussed included complete tumor regression shown up to 150 d
in a high expressing model at 1 mg/kg dosing. Also tumor initi-
ating cells are decreased by the APC treatment. In a Phase 1
trial, rovalpituzumab tesirine showed a 44% ORR and 78% clin-
ical beneﬁt rate in DLL3 high expressing patients and 23% ORR
and 68% clinical beneﬁt rate in all SCLC patients. A Phase 2
trial is expected to be initiated shortly.
Targeted protein therapeutics for the loco regional
and systemic treatment of cancer
After several short oral poster presentations, Gregory Adams
(Viventia Bio) presented work on targeted protein therapeutics
(TPTs) for the loco regional and systemic treatment of cancer.
TPTs are fully biologic fusion constructs containing antibody
fragments, a serum stable linker, and protein toxin payloads.
ScFvs, Fabs or diabodies are herein predominantly used for tar-
geting purposes. The conjugates exotoxin A or deBouganin
toxin can be linked to the antibody moiety by either non-cleav-
able or furin-cleavable linkers. Normal tissues express only low
levels of furin, which therefore should make the furin-cleavable
TPT predominantly active in cancer cells. The current pipeline
includes the locally-administered TPTs vicinium and proxi-
nium, both conjugated to an exotoxin A payload to target
EpCAM-expressing cells in high-grade non-muscle invasive
bladder cancer (NMIBC) and squamous cell carcinoma of the
head and neck (SCCHN), respectively. Systemically-adminis-
tered TPT VB6-845 d targeting EpCAM in solid tumors using
a deBouganin toxin was also discussed in more detail.
NMIBC accounts for 70–80% of all bladder cancers. The ini-
tial treatment for this stage of bladder cancer is currently surgi-
cal removal of the tumor and possible adjuvant treatment by
Bacillus Calmette-Guerin. New drugs for treatment are pre-
ferred and since EpCAM overexpressed in >97% of high grade
NMIBC, this creates a window of opportunity for vicinium.
Phase 1/2 results demonstrated a 41% CR at 3 months, no dose
limiting toxicity, and no MTD was reached during this study.
PK studies indicated that vicinium is not systemically absorbed,
but is contained within the bladder following intravesical instil-
lation. A subsequent Phase 2 study also showed promising efﬁ-
cacy results: 40% CR at 3 months, 17% overall CR at
12 months in the 12 week treatment arm and 13% overall CR
at 12 months in the 6 week treatment arm. The median time to
recurrence was 408 d and 274 d for the 12 week and 6 week
arm, respectively. The Phase 3 status and future plans were dis-
cussed, which showed that the treatment regimen was altered
without the necessity of a bridging study.
Proxinium is being evaluated for treatment of SCCHN,
which is the 7th most common cancer in the world, with
130.000 new cases per year and the current therapy being
highly invasive. The Phase 1 trial for this drug resulted in a
13% CR and 40% PR of evaluable patients, with an overall
tumor control rate of »80%. In a Phase 2/3 study with 166
patients, 40% increase of survival was noted by 6 wks, but the
trial was terminated prematurely. Proxinium has orphan drug
status in both the US and Europe and has been designated as a
Fast Track product by the FDA. A new pivotal Phase 3 study is
expected to be initiated by the end of Q1 2016.
Besides exotoxin A, deBouganin toxin is used as a payload,
which is a highly potent plant toxin in the picomolar range
that has been successfully de-immunized, while maintaining
its potency. The toxin was compared to DM1 and deBouganin
toxin was more potent against 3C HER2 breast cancer cell
lines and demonstrated a superior therapeutic window,
thereby limiting the potential for off-target toxicity. Addition-
ally, the deBouganin toxin is unaffected by multidrug resis-
tance (MDR) pumps, cannot bind and enter cells by itself and
is only cytotoxic when internalized. VB6-845, directed at
EpCAM and using deBouganin toxin as payload, was investi-
gated in Phase 1 trials for treatment of solid tumors. Initially,
no immunogenicity was observed for the toxin itself, however
the Fab-region of the product caused immunogenicity and the
trial was therefore terminated after 4 weeks. Five serious
adverse events (AEs) were reported, of which 2 were related
to the treatment (both infusion reactions). The VB6-845 Fab
has now been de-immunized and a non-human primate study
and Phase 1/2 study are expected for the future.
Wednesday December 9, 2015: Track A:
Immunotherapeutic antibody mechanisms
Chris Ullman
Combination immunotherapy for synergistic innate
and adaptive anti-tumor immunity
Dane Wittrup (Massachusetts Institute of Technology) chaired
the session and was the ﬁrst speaker. He ﬁrst noted that, in the
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past, understanding of immunotherapy was poor because
xenograft models lacked T cells. In these models, innate
effectors cells expressing FcgR were shown to be required
for the therapeutic effect of monoclonal antibodies, consis-
tent with the mechanism of ADCC. However, these effects
diminish when CD8C cells are depleted in immunocompe-
tent mice with isogenic tumors indicating a major role of the
adaptive immune system in addition to the innate. There-
fore, Prof. Wittrup and colleagues are investigating methods
that bolster both the innate and the adaptive immune
response using IL-2. IL-2 administered in combination with
mAbs has performed poorly due to the rapid clearance of
IL-2, but an extended half-life format of IL-2 fused to Fc
(Fc/IL-2) has shown synergistically activity with antibody
therapy in 4 different tumor models. The Fc/IL-2 molecule
fusion is a single murine IL-2 molecule fused with murine Fc
IgG2a containing a D265A mutant, which abrogates comple-
ment and Fc gamma receptor binding. Use of Fc/IL-2 dem-
onstrated beneﬁt of monotherapy and led to rapid
lymphocyte inﬁltration at the periphery and within the
tumor mass and necrosis, with large increases in T cell popu-
lations and NK cell populations. Nearly all cytokines were
elevated indicating a cytokine storm, in particular IL-6, IL-
1a, IL-1b, and neutrophil-related factors such as G-CSF and
MIP-2, causing inﬂammation and tumor killing through acti-
vation of intratumoral NK cells and intratumoral CD8C T
cells. However, T cells alone contributed signiﬁcantly to the
anti-tumor response, producing IFNg in response to therapy.
In order to prove their importance, the numbers of tumor
speciﬁc CD8C T cells (Pmel-1) were increased through
adoptive transfer in combination with Fc/IL-2 and TA99 a
monoclonal against TYRP-1 (a melanocyte marker that
becomes surface-expressed on B16F10 melanoma in mouse
models). This treatment produced 23/25 cures and immuno-
logical memory in a mouse B16F10 melanoma model.21,22
The Fc/IL-2 fusion protein has been formulated into a 4
component vaccine (named AIPV) that includes TA99
mAb, Fc/IL-2, anti-PD-1 and a peptide vaccine CD8 T cell
epitope derived from a melanocyte differentiation antigen
tyrosinase-related protein 2 (TRP2180-188). This immuno-
therapy seeks to provide an adaptive-centric (lymph node
targeting vaccine and anti-PD-1 checkpoint blockade) and
innate-centric (anti-tumor antibody and Fc/IL-2) method
for cancer treatment. This was demonstrated to successfully
treat B16F10 melanoma and TC-1 cervical cancer syngeneic
mouse models. Speciﬁcally, there was a progressive increase
of inﬁltrating T cells, a large increase in Teff/Treg ratios and
stable levels of T cells over 75 d or more. The serum from
AIPV-treated mice also displayed responses to many tumor
antigens and antigen presentation on dendritic cells was
critical for the success of AIPV therapy, as demonstrated in
Batf3¡/¡ mice. In the melanoma B16F10 melanoma metas-
tasis model, there was a 100% response. Therefore, the con-
clusion of the study was that the vaccine functions on the
tenet that Fc/IL-2 drives an essential T cell response, but
the NK response is dispensable; anti-PD-1 sustains the
response and peptide vaccine promotes the ampliﬁcation of
T cells. Opsonization of the tumor with antibodies also ulti-
mately helps drive the T cell response.
Unmasking cancer to innate sensing by Anti-CD47
antibody triggers adaptive immune-mediated tumor
destruction
The importance of the T cell response was re-iterated by
Yang-Xin Fu (The University of Chicago), who stated that
the adaptive T cell response is necessary for therapy; anti-
bodies help to increasing the stress in tumor tissue through
ADCC. In some patients, it is apparent that there is an
endogenous anti-tumor lymphocyte repertoire that can be
reactivated for therapy by immune modulators such as
checkpoint inhibitors. CD47 is cell surface ligand that is
highly expressed on stem cells and neoplastic cells provid-
ing a “don’t eat me signal” to protect against phagocytosis,
binding to signal regulatory protein a (SIRPa) on phago-
cytes. This results in phosphorylation of immunoreceptor
tyrosine-based inhibitory motifs (ITIMs) on SIRPa and
recruitment of Src homology phosphatases 1 and 2 (SHP-1
and SHP-2), both of which inhibit accumulation of myosin-
IIA at the phagocytic synapse. Anti-CD47 antibodies can
force the “don’t eat” message of the cell into an “eat me”
signal through blockade, leading to a potent anti-tumor
effect that was initially believed to be mediated by macro-
phage phagocytosis in xenograft models lacking adaptive
responses. However, in syngeneic tumor models in immu-
nocompetent mice, the anti-tumor effects of CD47 blockade
have recently been shown to be driven by dendritic cells
(DC) that cross-prime T cells within the tumor microenvi-
ronment. Therefore, the therapeutic effect of anti-CD47
depends upon type I/II interferons, dendritic cells (DCs)
and CD8C cells, supporting the notion of requiring both
the innate and the adaptive immune processes. Responses
to these signals generate immunological memory in BALB/c
mice inoculated with CD47C A20 B cell lymphoma cells.23
In order to determine the underlying mechanism of DC cell
activation, it was found that disrupting IFNAR1 receptor
function on DCs abrogated the anti-CD47 response,
whereas MyD88 and Trif activation were not necessary,
suggesting the involvement of a toll-like receptor-indepen-
dent mechanism. This action is orchestrated through a cyto-
solic DNA-sensing pathway by the endoplasmic reticulum–
resident protein stimulator of interferon genes (STING), a
signaling molecule directing the innate response to cytosolic
nucleic acids following phagocytosis. Hence phagocytic
uptake by DCs ultimately leads to production of type I
IFNs causing stimulation of DCs in an autocrine and para-
crine manner and cross-presentation of tumor-associated
antigens to activate tumor-speciﬁc CD8C T lymphocytes.23-
25
Another challenge is to understand why only a fraction
of patients respond to checkpoint inhibitors and to deter-
mine whether tumor inﬁltrating lymphocytes (TILs) are a
pre-requirement for an anti-tumor response. Tumors caused
by mouse MC38 colon adenocarcinoma cells respond well
to anti-PD-1 treatment and are known to be responsive to
T cell inﬁltration, whereas tumors formed from the murine
ﬁbrosarcoma cell line Ag104Ld do not respond. This anec-
dotally suggests a role for T cell inﬁltration as Ag104Ld
cells secrete high levels of suppressive TGF-b1. Indeed, the
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beneﬁcial anti-PD-1 effects were diminished by action of
the drug FTY720 drug (ﬁngolimod) that prevents T cell
inﬁltration. Conversely, a TNF superfamily ligand, TNFSF14
(also known as LIGHT), can cause T cell inﬁltration and
tumor regression by modulating T cell immune responses
by signaling through herpes virus entry mediator (HVEM)
and lymphotoxin b receptor (LTbR). LIGHT is predomi-
nantly expressed on lymphoid tissues, on the surface of
immature DCs and activated T cells. Interaction of LIGHT
with LTbR on stromal cells results in the upregulation of
lymphoid chemokines and adhesion molecules, leading to
the increased presence of lymphocytes in peripheral tissues.
LIGHT can also serve as a critical ligand for the activation
of NK cells. Intratumoral adenoviral delivery and expression
of LIGHT can result in rapid rejection of tumors in a NK-
dependent fashion through direct activation of tumor-spe-
ciﬁc cytotoxic T lymphocyte (CTL) proliferation and matu-
ration. In addition, metastases initiated by 4T1 or Ag104Ld
cells can also be eradicated by generation of a tumor-spe-
ciﬁc CTLs that exit the primary tumor site and inﬁltrate
distal tumors.26 LIGHT can be used in combination with
monoclonal antibody therapy and checkpoint inhibition to
cause T cell inﬁltration prior to anti-PD-1 treatment.
Activating and suppressive signals in the head and
neck cancer microenvironment affects therapeutic
mAb immunotherapy
The immune response in the clinical setting was described by
Nicole Schmitt (Johns Hopkins University), based on analysis
of cetuximab monotherapy and combination therapy adminis-
tered to head and neck cancer patients. EGFR is overexpressed
in over 90% of head and neck squamous cell carcinoma
(HNSCC) cancer patients and, therefore, is an attractive target
for cetuximab (an anti-EGFR mAb) therapy. However, HNSCC
is an immunosuppressive disease, with low lymphocyte levels,
impaired NK cell activity, and impaired ADCC. In addition,
Tregs have been linked to HNSCC tumor progression. There-
fore, immunomodulatory therapies that overcome immune
suppressive signals in patients with HNSCC have therapeutic
promise.27
Preliminary analyses indicate that PD-L1 is expressed in
50% to 60% of HNSCCs and that tumor inﬁltration by PD-1-
positive Tregs may be more common for HPV-positive than
HPV-negative HNSCCs in the tumor microenvironment. In
addition, EGFR prevents IFNg-mediated PD-L1 upregulation
suggesting potential synergy through combination. Anti-PD-
L1 is being tested in Phase 2 and Phase 3 trials against plati-
num refractory HNSCC and recurrent/metastatic HNSCC,
anti-PD-1 is being evaluated for platinum-cetuximab refrac-
tory HNSCC in Phase 2 and both anti-PD-1 and PD-L1 are
being separately tested against solid tumors (HNSCC) at
Phase 1. Cetuximab therapy can increase the frequency of
CTLA-4C Tregs and despite elevated levels of EGFR speciﬁc T
cells intreated patients compared to na€patients, only 15% to
20% of patients respond. These facts support the use of
CTLA-4 blockade in patients treated with cetuximab (Phase 1
trial). A small molecule TLR8 agonist (VTX-2337) and cetuxi-
mab, in combination with platinum/ﬂuorouracil are being
evaluated in a randomized Phase 2 clinical trial in ﬁrst-line
recurrent/metastatic HNSCC.27
Allogeneic IgG tumor therapy
Edgar Engleman (Stanford University School of Medicine)
presented research supporting the importance of DCs and T
cell responses in cancer immunotherapy, i.e., allogenic IgG
tumor therapy. DC therapeutic vaccines have been successful
in clinical trials for 5 disease indications, notably causing tumor
clearance in a patient with metastatic colon cancer as well as
some patients with non-Hodgkin’s lymphoma. Sipuleucel-T
(Provenge; APC8015) is the ﬁrst FDA-approved DC cancer
vaccine, speciﬁcally for the treatment of prostate cancer. For
sipuleucel-T, the vaccine preparatory process involves remov-
ing patient DCs and priming these cells with prostatic acid
phosphatase (PAP), which is present in 95% of prostate cancer
cells, and granulocyte-macrophage colony stimulating factor
(GM-CSF) for maturation of the DCs, and then administering
the primed cells back to the patient. The treatment can extend
the survival of patients with metastatic, asymptomatic hormone
refractory prostate cancer by 4.5 months, but has issues that
include the cost and the complexity of manufacturing, poorly
understood DC biology and susceptibility to immune escape
and immunosuppression. New methods are being developed to
activate DCs in vivo which take advantage of anti-tumor mech-
anisms of allo-immunity (an immune rejection of an allogenic
tumor) and appear to avoid the immune escape commonly
observed when autologous tumors are treated with therapeutic
vaccines or monoclonal anti-tumor antibodies. Application of
this phenomenon could provide the basis for inducing similar
responses against naturally arising tumors. The mechanism in
mice demonstrates the importance of anti-tumor IgGs that
opsonize disease tissue and bind DCs to allow internalization
and presentation of antigens to tumor reactive T cells. This was
shown by the induction of potent anti-tumor immunity in vivo
from bone marrow derived DCs (BMDCs) loaded with allo-
genic IgG immune complexes (IC), whereas BMDCs lacking
FcgR failed to induce an anti-tumor response. However, addi-
tional stimuli were necessary to activate quiescent tumor asso-
ciated DCs (TADCs) in situ. A combination of CD40L with
TNFa enabled stimulation of TADCs and allo-IgG-IC uptake.
Indeed, intratumoral injection of allogeneic IgG combined with
TNFa C CD40L induced complete elimination of B16 and LL/
2 tumors and almost complete eradication of lung metastases
from 4T1 breast tumor models following injection into the pri-
mary site. 28
The anti-tumor effect is explained as follows: TADCs are
quiescent and not naturally responsive to IgG-IC, requiring
stimulation to drive anti-tumor activity against autologous
tumors bound by allogenic IgGs; CD40L and TNFa stimulate
the DCs to internalize and present antigens, thus stimulating
tumor speciﬁc T cell responses. In this process, allogenic IgGs
enable higher levels of opsonization of tumor antigens. In con-
clusion, allogenic IgG (either natural or non-natural) adminis-
tration and DC stimulation offer another mechanism to
remove the brakes on the immune response as demonstrated
by high-potency in preclinical mouse models of melanoma,
breast, colon, pancreas, and lung cancer.
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Therapy-induced antibody responses
Catherine Sabatos-Peyton (Novartis) continued the focus on
checkpoint inhibition with a presentation looking beyond the
blockade of CTLA-4/PD-1. Multiple strategies are emerging to
target the immune system as exempliﬁed through the comple-
mentary combination of nivolumab and ipilimumab for treat-
ment of BRAF V600 wild-type unresectable or metastatic
melanoma. However, the tumor microenvironment is complex
and other checkpoint molecules, such as LAG-3 and TIM-3,
are important for offering opportunities for therapeutic inter-
vention, especially as other receptors are upregulated in PD-L1
deﬁcient cells. Indeed, combinations of PD-1 and LAG-3 or
PD-1 and TIM-3 blockade have proved to be synergistic and
more effective than monotherapy. Both have functions to regu-
late the immune system: TIM-3 is inversely correlated with IL-
12 production from TLR-stimulated macrophages, and LAG-3
is upregulated on natural and induced Tregs; LAG-3 Tregs are
potent suppressors.
Sabatos-Peyton described a Novartis anti-LAG-3 antibody
(LAG525) that binds to domain 1 of LAG-3 with picomolar
afﬁnity (KD 109 pM) and to human LAG-3-expressing cells
with a KD of 1.92 nM and cynomolgus monkey LAG-3-express-
ing cells with a KD of 2.3 nM. Anti-LAG-3 antibody blocked the
interaction between LAG-3 and MHC class II molecules on
Daudi cells with an IC50 of 5.5 nM, compared to a human
IgG4 isotype control. Blockade of LAG-3 and PD-1 potentiates
cytokine secretion. LAG525 is being tested at Phase 1/2b in
combination with PDR001, anti-PD1 monoclonal antibody.
Anti-CD8 Immuno-PET detection of anti-tumor
immune responses
Due to the critical role tumor-inﬁltrating cytotoxic CD8 T cells
play in determining anti-tumor immune responses, an anti-
CD8 antibody fragment was developed for immuno-PET detec-
tion of CD8 T cells. As discussed by Richard Tavare (David
Geffen School of Medicine at UCLA), anti-CD8 immuno-PET
successfully detected alterations in tumor-inﬁltrating CD8 T
cells in response to various methods of immunotherapy.
Track B: Target, target, target… it’s all about the
target
Thierry Wurch
This session was co-chaired by Janice Reichert (Reichert
Biotechnology Consulting LLC) and Janine Schuurman
(Genmab). Dr. Reichert opened the session by presenting a
brief but complete overview of the evolution of targets that are
tackled by antibodies in current clinical trials and on the mar-
ket. The main message was that, although there seems some
clustering around a few targets, most of the targets to which
these antibodies bind are unique. Some examples in the oncol-
ogy ﬁeld: 8 mAbs target the immune checkpoint axis PD-1/
PD-L1, same number for HER3. Five mAbs directed against
each of the 2 tyrosine kinase receptors EGFR and c-Met are
also in the clinic. Nevertheless, about 70 mAbs currently in
clinical development in oncology are directed against unique
targets. A similar situation is found outside oncology. A
complete review of the most exiting mAbs currently in early to
late stage clinical development can be found in latest article of
the ‘Antibodies-to-watch’ series by Dr. Reichert.29 The session
covered several of the most studied targets in oncology and
other indications, either by conventional antibodies or next-
generation protein scaffolds such as DARPINs.
HER2: Trastuzumab - 17 years and still going strong
Gail Lewis Phillips (Genentech/Roche) focused on the
tumor-antigen HER2 (or HER2/neu). A comprehensive
overview of Roche/Genentech around their product portfo-
lio built around the HER2 target was presented. HER2
(human epidermal growth factor receptor 2, also known as
HER2/neu) is a membrane tyrosine kinase receptor that,
when activated, affects cell proliferation and survival.30
HER2 ampliﬁcation is the primary pathway of HER2 recep-
tor overexpression and is a major driver of tumor develop-
ment and progression in a subset of breast cancers. HER2
is ampliﬁed in about 15% to 20% of breast cancers. The
value of HER2 as a therapeutic target encompasses 2
entirely different mechanistic dimensions. The ﬁrst
approach exploits the fact that HER2 is clearly a disease-
driving oncogene to deliver HER2 kinase inhibitors, appar-
ently a highly rational approach to the treatment of HER2-
ampliﬁed cancers.30 However, the functionally relevant
HER2-HER3 complex has proven much more difﬁcult to
inhibit than had been anticipated, and because of its modest
efﬁcacy, molecules targeting this hetero-dimeric complex
such as pertuzumab and lapatinib are currently used pre-
dominantly in combinations and in very advanced stages of
disease.30,31 The second approach exploits the massive cell
surface expression of HER2 and delivers of a variety of
cytotoxic or immunologic effectors with great selectivity to
these cancer cells. This approach has proven transformative,
essentially thanks to the antibody-drug conjugate ado-tras-
tuzumab-emtansine (Kadcyla).32 The clinical development
strategy for trastuzumab was described, going from the reg-
istration trials in advanced metastatic HER2-positive breast
cancer patients to the most recent trials and approval in
adjuvant setting.30 The importance of the development of a
diagnostic assay allowing identiﬁcation of the breast cancer
population showing very high HER2 expression status was
also highlighted.30 The existence of such an assay ready for
early clinical trials was pivotal for the success of the
molecule.
In a second part of her talk, pertuzumab (Perjeta) was
presented. Its main difference compared to trastuzumab
resides in the targeted epitope, preventing HER2 from
forming heterodimers with other HER receptors.31 Inhibi-
tion of HER2 signaling results in a reduction of tumor cell
proliferation, invasiveness and survival. Pertuzumab and
trastuzumab bind to different sites on the HER2 receptor
and clearly have complementary anti-tumor activities; they
act synergistically in inhibiting the growth of HER2-overex-
pressing breast cancer cell lines in vitro.31 The efﬁcacy of
pertuzumab in combination with trastuzumab plus doce-
taxel in the ﬁrst-line treatment of HER2-positive metastatic
breast cancer was demonstrated in the randomized, double-
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blind, placebo-controlled, multinational, Phase 3 CLEOPA-
TRA trial.31 Pertuzumab had an acceptable tolerability pro-
ﬁle when added to trastuzumab and docetaxel in the pivotal
CLEOPATRA trial.31
The last part of the lecture was dedicated to the ADC T-
DM1. This molecule is comprised of a potent cytotoxic
drug, maytansine, connected via a stable linker to trastuzu-
mab.32 A Phase 2 randomized trial of T-DM1 in the front-
line metastatic breast cancer setting revealed promising
activity and improved safety compared with standard che-
motherapy plus trastuzumab.32 Subsequently, EMILIA a
Phase 3 trial in patients with trastuzumab-pretreated meta-
static breast cancer showed T-DM1 to be associated with
prolonged progression-free and overall survival compared
with lapatinib plus capecitabine.32 T-DM1 represents a
major shift in the treatment of patients with breast cancer
as it replaces traditional non-targeted chemotherapy with a
medication that directs the cytotoxic therapy to cancer cells
by using a known biomarker.32
Targeting the receptors of TNF
The second talk was given by Allart Stoop (Rositys Ther-
apeutics) and described the various therapeutic modalities
to target tumor necrosis factor a (TNF) for the treatment
of chronic inﬂammatory diseases. TNF is a pleiotropic
cytokine associated with both inﬂammatory and immuno-
regulatory activities.33 Its relevance to disease is well
established and treatment with TNF antagonists has been
highly efﬁcacious in a range of inﬂammatory disorders,
e.g., rheumatoid arthritis.33 From a biological perspective,
TNF mediates its effects by signaling through 2 distinct,
speciﬁc, high-afﬁnity receptors.33 TNFR1 is expressed
ubiquitously and signals through an intracellular death
domain (DD), inducing apoptosis and NF-kB mediated
inﬂammation. In contrast, TNFR2 is expressed on a
restricted subset of cells, including endothelial cells and
cells of the immune system (T cells), has a TNF receptor-
associated factor (TRAF) signaling domain, and has been
associated with Akt/PKB-mediated repair and migration.33
Both TNF receptors signal as membrane-anchored recep-
tors and their numbers are regulated through a combina-
tion of receptor synthesis, internalization and shedding,
resulting in circulating soluble TNFR1 and TNFR2.33 As
the majority of detrimental effects seem to be mediated
by TNFR1 and the more beneﬁcial processes by TNFR2,
selective binders to TNFR1 antagonists need to be devel-
oped. A small, domain antibody (dAb) with monovalent
binding to TNFR1 was screened and characterized.
DMS5540 corresponds to a mouse TNFR1 antagonist,
constituted by the genetic fusion product of an anti-
TNFR1 dAb with an albumin-binding dAb (AlbudAb).34
It bound mouse TNFR1, but not human TNFR1, and was
an antagonist of TNF-mediated cytotoxicity in a L929 cell
assay.34 Surprisingly, the dAb did not compete with TNF
for TNFR1-binding. Pharmacokinetic studies of DMS5540
in mice over 3 doses (0.1, 1.0 and 10 mg/kg) conﬁrmed
extended in vivo half-life, mediated by the AlbudAb.34
Target engagement was further conﬁrmed by dose-
dependent increases in total soluble TNFR1 levels. Func-
tional in vivo activity was demonstrated in a mouse chal-
lenge study, where DMS5540 provided dose-dependent
inhibition of serum IL-6 increases in response to bolus
mouse TNF injection.34 Nevertheless, TNFR2 signaling
has been shown to promote regulatory T cell function.35
Blockade of TNFR1 and TNRF2 led to increased effector
T cell activity, which was not observed after selective
TNFR1 blockade using DMS5540, suggesting an immuno-
regulatory role of TNFR2.35 In support of this, TNFR1
blockade, but not TNFR1/2 blockade, expanded and acti-
vated Treg cells.
35
PD-1: Nivolumab - A game changer in immuno-
oncology?
Brian Lestini (Bristol-Myers Squibb) presented an overview
of the current revolution existing in Immuno-Oncology
(IO) with the antibodies modulating the immune check-
point axis, and especially those targeting cytotoxic T lym-
phocyte antigen 4 (CTLA-4) or programmed death 1 (PD-
1). CTLA-4 blockade was translated to the clinic with a
fully human antibody to human CTLA-4 (ipilimumab,
Medarex, Bristol-Myers Squibb). Tumor regression was
observed in Phase 1/2 trials in patients with a variety of
tumor types, including melanoma, renal cell carcinoma,
prostate cancer, urothelial carcinoma, and ovarian can-
cer.36,37 Ipilimumab (3 mg/kg) was approved in the USA
for ﬁrst-line and second-line treatment of patients with
advanced melanoma, and in second-line treatment in
Europe.37 This decision was based on trials showing that
ipilimumab alone or combined with a peptide vaccination
provided a 3.6 month median survival beneﬁt and a survival
beneﬁt of about 33% compared with vaccination alone.37
The optimum dose and schedule for ipilimumab is not
fully established.36 Good biomarkers for response are elu-
sive. Immune-related adverse events, an increase in lympho-
cyte counts, and the presence of NY-ESO-1 antigen seem to
be associated with higher response rates.36 Ipilimumab is a
complex drug to give. Adverse events—mostly immune—
occur in 40% of patients, including skin rashes, colitis, hep-
atitis, and hypophysitis. Grade 3–4 adverse events occur in
less than 10% of patients, but can be fatal. Adverse events
usually resolve spontaneously or after steroid treatment, but
endocrine failure frequently needs permanent hormonal
supplementation.36 High-dose steroids are indicated for
severe immune-related adverse events, but sometimes anti-
TNF (inﬂiximab) might also be needed.36 Several other late-
stage clinical trials are currently ongoing to evaluate to use
of ipilimumab in other solid tumor indications such as
prostate cancer.
Another T cell intrinsic inhibitory pathway identiﬁed after
CTLA-4 was the one mediated by PD-1 (programmed death 1)
and its ligand PD-L1. PD-1 was initially cloned in 1992 in a
study of molecules involved in negative selection of T cells by
programed cell death in the thymus.38 PD-1 is expressed in
many tumors in response to inﬂammation and its engagement
on the lymphocyte surface of melanoma cells downregulates T
cell function.38 In preclinical models, PD-1-deﬁcient mice
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develop a strain-speciﬁc, delayed-onset, organ-speciﬁc autoim-
munity with incomplete penetrance, supporting a role of the
PD-1 axis in self-tolerance. In tumor-bearing immunocompe-
tent mouse models, PD-1 blockade inhibited hematogenous
dissemination of B16 melanoma cells and CT26 colon cancer
cells to the liver and lung, respectively, through an effector T
cell mechanism.38
Very large Phase 1 studies were run with 2 anti- PD-1
antibodies (nivolumab and pembrolizumab), including par-
allel expansion cohorts in various tumor indications (i.e.,
series of CHECKMATE studies: CHECKpoint Pathway
and nivoluMAb Clinical Trial Evaluation).38-40 Strong clin-
ical responses were rapidly observed with objective
response rates of more than 30%, and long-term beneﬁt
noted in most responding patients.39,40 Furthermore, the
expression of PD-L1 on the surface of tumor cells seems
to be a predictive biomarker. 39,40 Numerous clinical trials
are still ongoing either to explore novel potential indica-
tions and to study PD-1 blockers within combination
therapies.
Targeting VEGF and HGF: First-in-human phase 1
study – interim results of MP0250, the ﬁrst systemic
DARPin
After a refreshment break, Michael Stumpp (Molecular Part-
ners) presented a novel, non-Ig-based protein scaffold called
designed ankyrin repeat proteins (DARPIN).41,42 These are
artiﬁcial scaffolds based on human ankyrin repeat domain pro-
teins, which are abundant intracellular adaptor molecules that
bind to various proteins with different biological consequences,
such as inhibition of complex formation. 41 DARPINS are com-
posed of 2 to 4 randomized, genetically-fused repeats that are
ﬂanked by N- and C-terminal-capping repeats, which are
essential for efﬁcient folding and for avoiding aggregation.
DARPIN repeats consist of 33 amino acids and are composed
of 2 a-helices and a b-sheet with a molecular mass of between
14 and 21 kDa. Due to their stable structure, DARPIN are very
stable proteins. 41
Abicipar is the most clinically-advanced DARPIN. It is an
antagonist of vascular endothelial growth factor A (VEGF-A)
that inhibits all relevant subtypes of VEGF-A with very high
potency, and currently developed for wet age-related macular
degeneration (wet AMD) and diabetic macular edema (DME).
The combination of small size, high potency and long intra-
vitreal half-life offers the potential for less frequent injections
and higher therapeutic efﬁcacy. In Phase 2 studies, abicipar was
shown to provide at least equal or higher vision gains with the
potential for fewer injections in wet AMD compared to stan-
dard of care treatment as well as less frequent dosing regimen.
This product is developed by Pﬁzer/Allergan.
The next product presented by Dr. Stumpp was MP0250, a
multipathway DARPin that inhibits both VEGF and hepatocyte
growth factor (HGF) combined to 2 human serum albumin
(HAS) binding modules. It simultaneously targets tumor
stroma, proliferation, invasion, and metastasis. MP0250 is in
Phase 1 clinical studies in solid tumor cancers and hematologi-
cal malignancies, including 15 patients. MP0250 was well toler-
ated at doses ranging from 0.5 to 8 mg/kg given every 2 weeks
as intravenous infusion and a maximum tolerated dose has not
been reached. The most frequent AEs (CTC version 4.03) were
transient hypertension (47%), diarrhea (40%), fatigue (40%)
and nausea (40%). No anti-drug antibodies were detected
within the treated patients. Two patients yielded stable disease
for more than 12 months and 8 months, respectively. MP0250
showed a long half-life of around 12 days, giving the potential
of dosing every 3 weeks. Repeated dosing led to sustained expo-
sure throughout the treatment periods analyzed, the longest to-
date being 12 months.
Several immune-oncology projects have been started based
on the favorable physic-chemical and functional properties of
DARPINs, they are all in early discovery stage.
Stabilized receptors as antigens for GPCR-antibody
discovery
Cath Hutchings (Heptares Therapeutics) described the tech-
nology platform developed at Heptares to generate stabilized
receptors to increase the efﬁciency of drug discovery, especially
against G protein coupled receptors (GPCRs). The GPCR super-
family is the largest and single most important family of drug
targets in the human body. It plays a central role in many bio-
logical processes and is linked to a wide range of disease areas.
There are over 375 GPCRs encoded in the human genome, of
which 225 have known ligands and 150 are orphan targets.
GPCRs are the site of action of 25–30% of current drugs.
Drug discovery targeting GPCRs remains challenging how-
ever. In contrast to classes of soluble protein drug targets, such
as kinases and proteases, the understanding of GPCRs has been
severely hampered by the lack of structural and mechanistic
knowledge and an understanding of how compounds interact
with them. 43 The overriding problem is that GPCRs are very
unstable and lose their highly organized structure and activity
when taken out of the cell membrane. 43 Through the use of
protein engineering methods, mutations could be identiﬁed
that both increase the thermostability of GPCRs when puriﬁed
in detergent, as well as biasing the receptor toward a speciﬁc
physiologically relevant conformational state. The resultant sta-
bilized receptor (known as a StaR) can be puriﬁed in multiple-
milligram quantities, while retaining correct folding, thus
enabling the generation of reagents suitable for a broad range
of structural and biophysical studies. 43,44
Three examples of application of StaRs in drug discovery
were presented. The ﬁrst was an undisclosed target from which
a StaR was used to screen Morphosys’ Ylanthia antibody
phage library. Strong afﬁnity binders (>10 nM) with good cel-
lular binding properties could be identiﬁed.
The second example corresponded to the generation of
StaRs derived from the prototypical receptor b-1-adrenergic
receptor (b1AR) and the screening for mouse hybridoma using
various approaches.45 The antibodies bind diverse epitopes
associated with low nanomolar agonist activity at b1AR. In
vitro characterization also veriﬁed different antibody receptor
interactions reﬂecting the different epitopes on the extracellular
surface of b1AR to which the mAbs bind.45 The anti-b1AR
mAbs only demonstrated agonist activity when in dimeric anti-
body format, but not as the monomeric Fab format, suggesting
that agonist activation may be mediated through promoting
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receptor dimerization.45 Finally, at least one of these antibodies
exhibited in vivo functional activity, producing an increase in
heart rate consistent with b1AR agonism.
The third example was the solution of a 3D structure of the
human protease-activated receptor (PAR)2 in partnership with
AstraZeneca.
Comprehensive discovery of new immuno-oncology
targets for antibody therapy
Art Brace (Five Prime Therapeutics) described the drug discov-
ery engine set-up and developed at Five Prime Therapeutics.
Their technology includes a large library of secreted, extracellu-
lar proteins, derived from more than 100 distinct human tis-
sues, and comprising more than 5,700 human proteins. The
library contains proteins that are full-length, structurally com-
plete and biologically active. The second part of the technology
concerns complex, cell-based screening assays. Screens were
automated, built in-house and analyzed using proprietary soft-
ware. These platforms are associated with a protein expression
system, RIPPS (Rapid In Vivo Protein Production System). It
enables production and testing of the proteins from the secre-
tome library directly in vivo in virtually any rodent model of
disease and in high throughput.
Track C: Improving ADC properties, widening
therapeutic window or maximizing potency
Joost Melis
Volker Schellenberg (Amunix) introduced the speakers of
this special ADC track, which focused on improving ADC prop-
erties, widening therapeutic windows or maximizing potencies.
Advancing the dolaﬂexin platform and other ﬂeximer-
based ADCs toward the clinic
Timothy Lowinger (Mersana) discussed advancing the dola-
ﬂexin platform and other ﬂeximer-based ADCs toward the
clinic. The dolaﬂexin platform is the most advanced at Mersana
establishing a DAR of »15 of a proprietary auristatin payload
and using a fully biodegradable ﬂeximer polymer. The dola-
ﬂexin intracellular processing of an auristatin derivative (AF-
HPA) with a cleavable linker exerts cell killing potency in the
sub-nanomolar range upon internalization and metabolization.
The payload is freely cell permeable and therefore capable of
inducing bystander cell killing. However, the ADC product is
designed as a sort of hybrid and AF-HPA can be further metab-
olized in the cell to AF, which is charged and therefore a non-
cell permeable molecule without bystander capabilities. Tissue
accumulation of AF and AF-HPA products at a single time
point of 48 h in non-perfused, tumor-bearing mice after 5 mg/
kg dosing showed that of the released payload 90 ng/mL was
present in the tumor, of which 70% was AF and 20% AF-HPA.
Approximately 10 ng/mL was distributed to liver, spleen, and
kidney each, while very low concentrations were found in mus-
cle and plasma. The therapeutic index of dolaﬂexin (calculated
by the highest non-severely toxic dose in NHP (mg/m2) / low-
est dose inducing regressions in mouse xenograft (mg/m2))
compared favorably to other cleavable auristatin ADCs.
Currently, XMT-1522 is in late stage preclinical development
and expected to move to clinic in the ﬁrst half of 2016. The
ADC targets HER2 and is aimed at treating 1C, 2C, and 3C
HER2 tumors. HER2 1C/2C positive cancers make up about
60% of metastatic breast cancers in US and EU5. XMT-1522 is
built upon the HT-19 antibody that does not compete for bind-
ing with either trastuzumab or pertuzumab, but rather binds to
a unique epitope (not trastuzumab-based), and a DAR »15 is
enabled via Fleximer polymer conjugation. ADC sensitivity was
measured and benchmarked against Kadcyla. The dolaﬂexin
ADC exhibited single digit nanomolar potency in vitro across a
wide panel of cell lines with varying expression levels of HER2.
Potency was comparable to ado-trastuzumab emtansine
(Kadcyla) in very high expressing cell lines; in moderate
expressing cell lines (>10,000 HER2/cell) potency was signiﬁ-
cantly greater than Kadcyla; and in 40% of cell lines tested
with 0–10,000 copies of HER2 per cell single digit nanomolar
potency was maintained, with none of the cell lines being sus-
ceptible to Kadcyla. In vivo assessment using N87 and JIMT-
1 cell line models demonstrated 100% tumor free survivors at
lower dosages than Kadcyla. In a SNU5 gastric cancer model
with 22.000 HER2/cell, the drug showed also efﬁcacy (tumor
growth delay, no complete regression), again outperforming
Kadcyla. Triplet combination of XMT-1522 C trastuzumab C
pertuzumab showed improved efﬁcacy over single agent or
trastuzumab C pertuzumab treatments in a N87 xenograft
model. A resistance N87 model was developed using Kadcyla
treatment, resulting in a model that is 500x less sensitive to
Kadcyla but retains its HER2 expression levels. XMT-1522
treatment exhibited good to full tumor regression in this
Kadcyla-resistant model. In PDX models, like MAXF-1162
for breast cancer, complete tumor regression was also observed
for XMT-1522 and similar efﬁcacy was established in other
PDX models. Tolerability was assessed in NHP studies and
XMT-1522 showed an acceptable safety proﬁle that was com-
parable to Kadcyla. Mersana’s portfolio further contains an
undisclosed ADC targeting solid tumors, XMT-1535, of which
IND ﬁling is expected to be in 2017. MERS3-dolaﬂexin IND ﬁl-
ing is expected in 2018.
Probody therapeutics can redeﬁne the target
landscape for drug conjugates
Luc Desnoyers (CytomX) talked about the development of
ProbodyTM drug conjugates (PDCs). Probody therapeutics are
fully recombinant masked antibodies that are designed to
remain inactive in healthy tissue, but are activated speciﬁcally
in the tumor microenvironment. A masking peptide is tethered
recombinantly to the light chain of the antibody portion, which
is cleaved in the tumor microenvironment by protease activity
upon which antibody binding to the target is possible. This
approach is designed to blunt systemic toxicities that can be
associated with antibodies. Probody therapeutics can localize
activity to the tumor microenvironment, broadening the thera-
peutic window and enabling development of potent therapeu-
tics against novel targets. The most suitable masking peptide is
speciﬁc for each Probody therapeutic. The best masking pep-
tide is selected after panel screening, and can, for instance, be
selected based on cleavability, e.g., by one or by multiple
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proteases in the tumor microenvironment. The current pipeline
includes, among other modalities, PDCs targeted against
CD166 and CD71, and Probody therapeutics directed to T cell
engaging bispeciﬁcs and immune-oncology therapeutics, such
as PD-1 and PD-L1. Proof of concept data of an anti-EGFR
cetuximab Probody therapeutic were presented. IHZTM data
demonstrated that protease activity in the tumor microenviron-
ment is a lot higher than in healthy tissue in vitro and ex vivo.
Preclinical in vivo imaging data in mice demonstrated the same
accumulation proﬁle when the EGFR Probody therapeutic with
a cleavable linker was compared to cetuximab. A control with a
non-cleavable linker showed no accumulation at targeted sites.
Additionally, the Probody therapeutic revealed similar efﬁcacy
and improved safety proﬁles over the control antibody.
The CD166-directed Probody therapeutic was discussed in
more detail. The role of CD166 in cancer is not known, but the
target is highly expressed in prostate, breast, cervical, oropha-
ryngeal and lung cancers, as well as head and neck squamous
cell carcinoma. CD166 is, however, also expressed in many nor-
mal tissues, which suggests that it is not a good target for a tra-
ditional ADC. IHZ data of the CD166 Probody therapeutic
showed no binding to normal healthy tissue, but it does bind at
tumor sites. In collaboration with ImmunoGen, the CD166-
SPDB-DM4 ADC was compared to the PDC. Both the PDC
and ADC demonstrated efﬁcacy in a triple-negative breast can-
cer and an ovarian cancer model, indicated by rapid tumor
regression with some regrowth after 1.5 months. Cynomolgus
monkey toxicity studies indicated that the PDC was well toler-
ated and the stability of the PDC is consistent with other
SPDB-DM4 conjugated antibodies. Standard DM4 toxicities
were apparent at 15 mg/kg dosing, and no off-target toxicity or
weight loss was observed. Liver toxicity markers were also not
altered by PDC treatment. IND ﬁling for this PDC is antici-
pated in the ﬁrst half of 2017. PROBODY and IHZ are trade-
marks of CytomX Therapeutics, Inc.
Developmental strategy of cancer stromal targeting
therapy
Masahiro Yasunaga (National Cancer Center) discussed a
developmental strategy of cancer stromal targeting (CAST)
strategy. Stroma consists of cellular components (ﬁbroblast,
endothelial, blood cells etcetera) and acellular (matrix, colla-
gen) elements and can cause autoimmune reactions. Stroma
can also create a barrier for efﬁcient antibody delivery to tumor
sites, which was exempliﬁed by staining collagen and identify-
ing barriers to tumor sites in malignant lymphoma and pancre-
atic cancer. CAST therapy was developed to improve antibody
delivery to the actual tumor site. This approach combines
administration of a tumor-targeting ADC with a stroma-target-
ing ADC to basically clear the path to the tumor site. Anti-col-
lagen and anti-ﬁbrin ADCs were developed to target tumor
stroma. Two types of linkers were developed for these ADCs, a
carbamate-bond (for intracellular release) and an ester-bond
(for extracellular release). The safety proﬁle of the anti-collagen
4 ADC was examined and indicated that AST and ALT levels,
plus white blood cell counts were acceptable. Also the anti-
Coll4 ADC did not induce arthritis in mice in contrary to an
anti-Coll2 ADC. In addition, an anti-ﬁbrin ADC was
developed. This ADC targets tumor stroma speciﬁcally, and
not healthy tissue, which is characterized by ﬁbrinogen. The
current stroma ADCs have a DAR of 3–4 and are payloaded
with MMAE, which is released gradually and distributed
throughout the tumor. Tailoring of stroma ADCs to individual
characteristics of each tumor stroma is preferred.
XTEN drug linkers with precisely controlled chemical
structures for high drug loads and optimized tissue
uptake
After a networking break, Volker Schellenberger (Amunix)
discussed XTEN drug linkers with precisely controlled chemi-
cal structures for high drug loads and optimized tissue uptake.
A common strategy for increasing therapeutic molecule half-
life is the chemical attachment of polyethylene glycol (PEG),
which increases the effective size of drugs and thus slows their
clearance from the bloodstream. This however results in non-
biodegradable, complex product mixtures that are difﬁcult to
purify and characterize. XTEN is a homogeneous biodegradable
polymer built from 6 amino acid types that are used to form the
backbone of precisely-controlled polymers. XTEN polymers
can be produced in a wide range of sizes from <10 kDa to
80 kDa. XTEN increases half-lives of therapeutic molecules, is
low immunogenic, soluble, stable, and well-tolerated. Recombi-
nant fusion or chemical conjugation to XTEN is possible, creat-
ing opportunities for immune activators (ProTIA) and drug
conjugates (XDC), for example the XDC FVIIIFc-VWF-XTEN.
The biological role of FVIII in the clotting cascade was brieﬂy
presented and it was demonstrated that half-life prolongation
for this XDC is beneﬁcial for clinic application. Tumor-speciﬁc
accumulation was demonstrated for an anti-HER2-XTEN of
which 40% of the product accumulated at the tumor site. The
anti-HER2-XTEN showed similar efﬁcacy results to Kadcyla
in vivo when using a 3, 10, or 30 mg/kg single dose. A long
term vision for XDCs is to create molecules that are large
within the blood stream, but once trafﬁcked to the tumor sites
become smaller by disposing parts of the molecule. This local-
ized size reduction would then facilitate tumor penetration.
XTEN polymers facilitate payloading antibodies with different
DARs (up to DAR 9 has been tested). Anti-folic acid XDC, FA-
XTEN431-DM1, internalized target speciﬁcally, plus demon-
strated in vivo efﬁcacy after single dosing, while no weight loss
was observed after treatment. Next, the ProTIA technology was
discussed, in which a XTEN polymer extends the half-life in
circulation of bispeciﬁc T cell engaging BiTE molecules and
prevents premature T cell activation since protease activation
near the tumor site is necessary to activate the BiTE. Produc-
tion of ProTIA is performed in E. coli and the characterization
of ProTIA was brieﬂy discussed. In vitro efﬁcacy was shown for
an EpCAM-ProTIA, which exhibited a half-life of 32 hours
compared to 3.5 hours of the targeting component only.
A meditope site-directed conjugation strategy
simpliﬁes antibody conjugation and provides a
unique way to improve internalization
Elisabeth Gardiner (Meditope Biosciences) presented a site-
directed conjugation strategy that simpliﬁes antibody
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conjugation and provides a unique way to improve inter-
nalization. A site-speciﬁc novel antibody platform (SnAP)
was developed in which a peptide is ‘locked’ in between
heavy and light chains of the Fab arms creating a so-called
meditope. The discovery of the SnAP binding site was pre-
sented. The peptide was discovered by a peptide binding to
cetuximab initially, binding between speciﬁc amino acids
on the heavy and light chain of the Fab region. These spe-
ciﬁc sites can now be engineered into all antibodies to
tweak peptide binding. Amino acids that can be engineered
are in a highly conserved area within the frame work
region, which makes SnAP engineering applicable to all
antibodies. The meditope site is distinct from antigen bind-
ing, so it does not interfere with target binding. Also, when
cytotoxins are conjugated to the peptide or fusion proteins
are made via the locked peptide, no interference with the
normal antibody function is apparent. Meditopes are now
available in non-covalent and covalent variants. Covalent
binding can be used for cytotoxin conjugation in which the
DAR is always conserved to 2. In addition, GFP attachment
to the peptide creates opportunities for imaging purposes,
radiolabeled attachment can generate new diagnostic tools
and the SnAP platform also facilitates possible manufactur-
ing strategies. Antibody to antibody interactions can be
promoted at the cell surface facilitated by meditope - anti-
body binding. Interactions at the cell surface will then
enhance internalization and cell death. Two- to 5-fold
increases of internalization were achieved compared to the
control antibodies.
Track A: Antibodies to harness the cellular immune
System
Jenny Yeung
The afternoon session of Track A was chaired by Kerry A.
Chester (University College London).
Engineering antibodies and T cell receptors by
mammalian display
Generation of immune-modifying binders is facilitated by
the availability of large libraries of antibodies or T cell
receptors expressed on the surface of mammalian cells. As
discussed by John McCafferty (IONTAS), scientists at ION-
TAS have demonstrated the construction and use of mam-
malian display libraries, facilitated by the use of site-speciﬁc
nucleases. Such libraries allow the screening of millions of
clones by ﬂow sorting while providing information on both
the level of expression and the extent of binding within
individual clones.
Targeting immune regulation at the tumor site
CTLA-4 is a co-inhibitory molecule expressed on T cells that is
implicated in the inhibition of T cell-mediated anti-tumor
activity and contributes to tumor immune escape. Clinical data
has shown that treatment with anti-CTLA-4 antibodies signiﬁ-
cantly improved survival rates of patients with advanced mela-
noma, many of whom have durable and long-term responses.
As discussed by Sergio A. Quezada (University College
London), understanding the mechanisms by which immune
modulatory antibodies exert their anti-tumor activity can help
develop strategies to maximize their activity. The tumor micro-
environment and Fc receptors have important roles in modu-
lating the in vivo activity of immunomodulatory antibodies.
The effectiveness of anti-CTLA4 therapy is not solely due to
blocking the inhibitory signals to effector T cells (Teff). Studies
have shown that CTLA-4 is expressed on Teff cells and on regu-
latory T cells (T reg). In both murine models and human mela-
noma patients, there is an altered balance in the ratio of Treg
and Teff cells within the tumor; speciﬁcally a higher proportion
of Tregs and a lower level of Teff exists. Although both Teff and
Treg cell populations expand in the lymph nodes of mice by
treating with anti-CTLA-4 antibodies, speciﬁc elimination of
Tregs within the tumor is promoted. Tregs expressed higher lev-
els of CTLA-4 than Teff cells, which leads to preferential deple-
tion through ADCC by tumor macrophages via an FcgR-
dependent pathway involving the FcgIV receptor. The isotype
of anti-CTLA-4 antibodies administered and therefore their
differential binding to Fc receptors was important for anti-
CTLA-4 anti-tumor activity.
Dr. Quezada noted that unpublished data using human
FcgR transgenic mice helped to determine whether the mecha-
nisms would also apply in the context of human FcgR rather
than murine FcgR. This model system showed that tumor-inﬁl-
trating macrophages and dendritic cells expressed high levels of
the activating human Fc receptors CD16, CD32a and CD64. A
mutant anti-CTLA4 hIgG1 antibody that had enhanced ADCC
activity prevented accumulation of Tregs in the lymph node and
enhanced elimination of Tregs within tumors, leading to an
increase Teff/Treg ratio. Further investigation using this model is
required to determine which human FcgRs are required,
whether anti-tumor activity is also enhanced, and whether
there would be enhanced toxicities.
Analysis of tumor inﬁltrating cells from human melanoma
patients provided evidence that the mechanisms identiﬁed in
the murine models was also potentially applicable to humans.
As in murine models, CTLA-4 was highly expressed by Tregs in
human melanoma tumors and some of the tumors showed
high inﬁltration of macrophages (CD11bC/FcgRC cells).
Freshly isolated human tumor macrophages were capable of
mediating anti-CTLA-4 activity in vitro.
Characterization of the expression of immune checkpoints
in human cancer can help develop new and more effective
immunomodulatory agents and combinations. Analysis of
human melanoma tumor inﬁltrating lymphocytes showed
that the activating receptors OX-40 and GITR are more
highly expressed on Tregs than on Teff cells. In particular, the
expression pattern of GITR closely resembled that of CTLA-
4 on Tregs and Teffs. Mouse models showed that agonistic
anti-GITR antibodies require ADCC for depletion of intratu-
moral Tregs and maximal activity was dependent on the anti-
body isotype.
Studying changes that occur in the tumor microenviron-
ment pre- and post- therapy, may help understanding of the
resistance to checkpoint inhibition, and facilitate the develop-
ment of optimal combination therapies to maximize anti-
tumor activity.
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An Anti-ICOS agonistic antibody for cancer
immunotherapy
Jennifer Michaelson (Jounce Therapeutics) discussed the com-
pany’s program to develop an agonistic antibody to the co-
stimulatory molecule ICOS. Preclinical studies demonstrated
that anti-ICOS agonistic antibodies are efﬁcacious in syngeneic
tumor models, with enhanced efﬁcacy observed in combination
with PD-1 inhibition.
Characterization and in vivo evaluation of blocking
antibodies against GARP, a novel immune checkpoint
target
Activated regulatory T cells (Tregs) speciﬁcally express the pro-
tein GARP (Glycoprotein A Repetitions Predominant), which
is not expressed on other T cell subsets. On activated Tregs,
GARP forms a complex with latent TGF-b1. GARP is key to
the release of TGF-b1, speciﬁcally at the Treg level, and results
in stimulation of Tregs and inhibition of effector T cell func-
tions. Locking of TGF-b1/GARP complex by antibodies can
potentially prevent release of active TGF-b1, leading to
decreased Treg and can ultimately lead to inhibition of immune
escape and increased anti-tumor activity in local
microenvironments.
Michael Saunders (argenx) described 2 anti-human GARP
antibodies, one murine and one from llama, were identiﬁed
and engineered with human IgG backbone that recognized the
GARP/TGF-b1 complex. These antibodies inhibited TGF-b1
activation on Tregs by blocking release. This inhibits SMAD2
phosphorylation, suppressing helper T cell proliferation. A
xenogeneic graft-versus-host disease (GVHD) murine model
was used to demonstrate the Treg inhibitory effects of anti-
GARP antibodies. In this model, the presence of human Tregs
protects against GVHD whereas treatment with e.g., nivolumab
(anti-PD-1) aggravates GVHD. Anti-GARP antibodies were
shown to ablate the protective activity of Tregs by speciﬁcally
blocking their function without depleting their numbers. These
data showed that GARP function had certain similarities with
CTLA-4 functionality.
Exploratory toxicology studies in cynomolgus monkey stud-
ies were performed, using the llama anti-GARP antibody clone
LHG10.6, upon which ARGX-115 is based. GARP is also
expressed on platelets and liver stellate cells and could poten-
tially affect platelet counts and liver function. However, in vitro
assays showed no issues with thrombin- or collagen-induced
platelet activation. Monkeys being given 3 doses at 14 day inter-
vals at 0.5 mg/kg or 10 mg/kg showed no effect on platelet
counts, coagulation parameters, or liver functions after being
examined for 26 d after the last dose.
ARGX-115 is a high afﬁnity (40 mM) antibody targeting the
GARP-TGFB1 complex and has development potential as a
ﬁrst-in-class immune-oncology product. It has a novel model
mode-of-action where TGFB1 is speciﬁcally targeting and
inhibiting the suppressive effects of Treg function within the
tumor microenvironment without depleting Treg systemically.
This offers advantages over targeting CTLA-4 for future combi-
nation therapy.
Engineering agonistic anti-TNFR antibodies
Ann White (University of Southampton) discussed immu-
nostimulatory monoclonal antibodies that can augment
anti-tumor immunity through activation of tumor necrosis
factor receptor (TNFR) family members, such as CD40.
Binding of CD40 on cells such as dendritic cells and B cells
to its ligand CD40L leads to clustering of CD40 and subse-
quent activation of numerous immune mechanisms, which
lead to anti-tumor activity. Multiple mechanisms of TNFR
monoclonal antibody agonistic activities discussed are
mediated through the Fc region or through the variable
domains.
Anti-CD40 antibodies have shown efﬁcacy in preclinical
mouse models. The ratio of activating FcgR binding to
inhibitory FcgR binding (A/I ratio) is low for mIgG1 and
higher for mIgG2a, which contributes to their different
effects on anti-tumor activity in BCL1 lymphoma tumor
model. Anti-CD40 mIgG1 antibodies induced survival and
improved CD8 T cell responses in mice, whereas mIgG2a
anti-CD40 antibodies did not. Binding to inhibitory
FcgRIIB receptor was shown to be essential for mIgG1
anti-CD40 activity and CD8 T cells responses in FcgRIIB
knock out mice. FcgRIIB was also essential for B cell activa-
tion induced by anti-CD40 antibodies. The role of FcgRIIB
in anti-CD40 therapy in these models was to act as a cross-
linking scaffold that increased clustering of CD40 molecules
and subsequent activation of T and B cells. These may be
general mechanisms that are also relevant to other TNFRs
including human 4–1BB, OX40 and CD28.
Choosing the optimal isotype for development of clinical
anti-human CD40 is a critical factor. Anti-human CD40
(LOB7/4) was cloned to different human IgG isotypes. Only
the IgG2 isotype variant demonstrated strong agonist activ-
ity in vitro, but does not bind to FcgRIIB. hIgG2 exists as
H2A or H2B isoforms due to rearrangement of disulﬁde
bonds within the hinge and CH1 domains. Mutagenesis can
lock them on one form or the other. H2A has a more ﬂexi-
ble conformation while H2B has a much more compact and
rigid structure. While there is no difference in binding to
CD40, H2B anti-CD40 has much better agonistic activity
compared to H2A both in vitro and in vivo. The rigid
structure of the H2B form resulted in tighter clustering of
CD40 molecules upon binding, conferring to better agonis-
tic activity.
Where anti-CD40 antibodies bind on the CD40 molecule also
inﬂuences their agonistic properties. Comparison of 3 different
anti-CD40 antibodies, ChiLOB7/4, SGN40, and CP870893,
showed that they bound similar epitopes on the CD40 CRD1
domain and conferred better in vitro B cell proliferation and in
vivo CD8 T cell expansion, but antibodies that recognize more
proximal domains (CRD2 and CRD3–4) did not.
Antibody engineering can optimize and improve the
therapeutic activity of clinical antibodies against TNFR fam-
ily members. These can act through FcgR-dependent or
FcgR-independent mechanisms and can all contribute to
the development of better immunomodulatory anti-thera-
peutic agents.
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Track B: Antibodies for orphan indications
Joost Bakker
James Larrick (Panorama Research Institute and Veloc-
ity Pharmaceutical Development) chaired the morning
Track B session on the development of antibody therapies
for indications affecting small numbers of patients, i.e.,
orphan diseases.
Screening for GPCR antibodies with cell surface
displayed antibody libraries constructed by antibody
membrane switch technology
Bo Yu (Larix Bioscience) discussed the Antibody Membrane
Switch (AMS) technology, which is a unique switchable cell
surface antibody display technology that facilitates rapid
FACS-mediated identiﬁcation of high producing cell lines. Cell
surface displayed antibody libraries were constructed in CHO
cells using AMS technology. Antibodies with superior activities
against GPCRs were isolated by direct screening of binding
between the cell surface antibody and GPCRs on target cells.
Generating highly potent antibodies to a ligand-gated
ion channel
Ion channels are notoriously challenging targets for anti-
body therapeutics. Wendy Williams (MedImmune) pre-
sented new data on the generation of potent ion channel
modulating antibodies to a ligand-gated ion channel. She
discussed a case study on the discovery of ion channel
modulating antibodies, including insights into the successful
methods of identifying functional antibodies against these
targets.
Targeting the Kv1.3 ion channel with an engineered
ultralong CDR H3 cowbody
Cows can make unusual ultralong CDR3s that can range to
nearly 70 amino acids in length and are comprised of a b-strand
“stalk” and disulﬁde bonded “knob.” The knob region is similar
in size, shape, and disulﬁde composition to several naturally
occurring venom peptides that inhibit ion channels. Vaughn
Smider (The Scripps Research Institute) presented data on a
humanized cowbody with a Kv1.3 inhibitor venomous peptide
that showed potent inhibition of T cells, and could be a unique
antibody to treat autoimmune disease.
FFP104: A negative allosteric modulator of CD40
signaling
CD154-blocking mAbs used in human clinical trials resulted in
unanticipated vascular complications, leading to heightened
interest in the therapeutic potential of antagonist mAbs speciﬁc
for human CD40. Molecules of the CD40 pathway are (over)
expressed in primary biliary cirrhosis target tissue and involved
in target cell apoptosis. CD40 plays a central role in immune
responses, in B cell activation and macrophage stimulation.
Inhibition of the CD40 pathway could thus interfere with the
development of autoimmune cholangitis.
Mark de Boer (Fast Forward Pharmaceuticals) discussed the
mechanism of action of anti-CD40 mAb FFP104. FFP104 is
originally derived from murine 5d12 and antagonizes CD40-
CD154 signaling. Interestingly, it does not require physical
competition with CD154 to inhibit CD40 signaling and thus
acts as a negative allosteric modulator of CD40 signaling. Fur-
thermore, FFP104 inhibits CD154-mediated B cell activation.
In addition, binding of FFP104 to CD40 induced degradation
of TRAF2 and -3.46 Validation in primate models has been per-
formed, where a reduction of germinal centers was observed
after FFP104 administration, which is consistent with the phe-
notype in CD40L-KO mice.47
FFP104 is currently being tested in a Phase 2a clinical study
in primary biliary cirrhosis. In this disease, CD40-L-bearing T
cells and CD40-L-bearing macrophages seem to induce apopto-
sis of biliary epithelial cells.48 FFP104 can inhibit apoptosis
induction by T cells. Also in a clinical Phase 1/2 trial in Crohn’s
disease, the number of inﬁltrating lymphocytes decreased after
administration of FFP104.
ARGX-113, a novel Fc-based therapeutic approach for
antibody-induced pathologies
Peter Ulrichts (argenx) discussed ARGX-113, a proprietary
antibody fragment, based on the company’s ABDEG technol-
ogy. ARGX-113 works by preventing pathogenic autoantibod-
ies from being recycled, promoting their degradation and
thereby clearing them from circulation. Preclinical data in cyn-
omolgus monkeys proved ARGX-113 to be highly effective in
rapidly eliminating pathogenic antibodies, while sparing the
broader immune response. The data support further clinical
development of this novel therapeutic approach in autoim-
mune disease management.
Anti-LRP6 antibody attenuates Wnt pathway-
mediated pathologies
In general, Wnt signaling orchestrates wound healing, repair
and regeneration. Tuning Wnt signaling can enhance wound
repair. Elevated Wnt signaling is also observed in human reti-
nas of patients with diabetic retinopathy and various ﬁbrotic
diseases.
As described by James Larrick, both LRP5 and LRP6 are
potential targets, but LRP6 is preferred, because it is required
for upstream signaling of VEGF and CTGF. LRP6 also controls
proﬁbrotic signaling. Activation of the Wnt pathway via LRP6
cell surface signaling contributes to the severe retinal/choroidal
neovascularization observed in VLDLR knockout mice.
Dr. Larrick and colleagues identiﬁed a novel murine mono-
clonal antibody (2F1) that antagonizes LRP6 activity and dem-
onstrated signiﬁcant inhibitory activity in numerous animal
models. The antibody directly inhibits Wnt signaling and
downregulates LRP6 cell surface expression.
Wnt pathway is activated in human retina in diabetes. The
2F1 antibody inhibits high glucose-induced endothelial cell
migration and tube formation. Inhibition of pathology in mul-
tiple forms of eye disease was also observed in a rat model
(streptozotocin diabetic rats). In a model of wet AMD, lesion
size was found to be reduced. Also in another mouse model for
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wet AMD, 2F1 inhibited cytokines and VEGF production. Ben-
eﬁt was also observed in dry AMD models and in chronic
mouse models for eye disease via inhibition of WNT signaling.
The 2F1 was humanized using PDL technology. The product,
H1L1, attenuated topical alkali burn injury and inhibited
inﬂammation in the eye in preclinical models. These data sup-
port clinical development of this novel therapy for a number of
conditions including AMD, diabetic retinopathy and ﬁbrotic
diseases.
Track C: Preclinical and clinical ADC data
Joost Melis
The afternoon session of this special ADC track was chaired
by Mark Alfenito (EnGen Bio, Inc.).
Engineering and optimization of antibodies for ADCs
Lioudmila Tchistiakova (Pﬁzer) discussed engineering and
optimization of antibodies for ADCs, describing several exam-
ples. ADCs are complex modalities that require optimization of
each component (e.g., antibody vehicle, linker-payload, conju-
gation strategy), and the bigger picture needs to be taken into
account. Candidate selection for a 5T4 ADC antibody for
instance resulted in 2 favored ADC candidates: A1 and A3.
ADC A3 showed a higher afﬁnity and higher in vitro potency
when compared to A1, but A1 demonstrated a greater thera-
peutic index than A3 and was therefore ﬁnally selected as a
lead candidate. Selection of the antibody binding epitope for an
ADC is also crucial, as was indicated by examples related to 2
anti-Notch3 antibodies with distinct mechanisms of action
(inhibitory vs non- inhibitory). Epitope mapping revealed dis-
tinct yet overlapping epitopes that were consistent with the
effects on signaling activities of both antibodies. Despite antag-
onizing NOTCH3 signaling, the inhibitory anti-NOTCH3 anti-
body was unable to induce regression in preclinical tumor
xenografts with active NOTCH3 signaling. To enhance their
potency, both classes of anti-NOTCH3 antibodies were conju-
gated to an auristatin-based microtubule inhibitor via a cleav-
able linker. Unexpectedly, the inhibitory anti-NOTCH3
antibody demonstrated more rapid trafﬁcking to the lysosome
than the non-inhibitory antibody, suggesting that the 2 anti-
bodies have distinct internalization routes with important
implications for NOTCH3-ADC pharmacology. Furthermore,
conjugation efﬁciency should be taken into account in ADC
development. Variable regions should not only be screened for
binding properties, but also for efﬁcient conjugation properties
for an ADC product. Additionally, ADC recycling via the FcRn
could affect the PK of the drug and screening IgG:FcRn com-
plex structures could be beneﬁcial for optimal candidate selec-
tion. Biophysical properties of antibodies should also be
assessed thoroughly. Setting up a robust characterization tool-
box for antibody ranking and selection is recommendable, for
example assessing afﬁnity, thermal and pH stability, aggrega-
tion propensity, microscale pH buffer scouting, viscosity scout-
ing etcetera. Antibody engineering for site-speciﬁc conjugation
allows improving ADC homogeneity, in vivo stability, PK and
has the potential to increase the therapeutic index.
SGN-CD33A: Preclinical and phase 1 clinical trial
results of a CD33-directed PBD dimer antibody-drug
conjugate for the treatment of acute myeloid
leukemia
Eric Feldman (Seattle Genetics) discussed vadastuximab talir-
ine (SGN-CD33A; 33A), a CD33-directed PBD dimer ADC for
treatment of AML. AML treatment has not meaningfully
changed in over 30 y. Outcomes in AML remain unsatisfactory,
and novel treatments are urgently needed. CD33 may be an
optimal target for ADC therapy of AML. »90% of AML
patients express CD33 on leukemic blasts. CD33 is also
expressed to a lesser extent on normal myeloid cell. 33A is a
cys-engineered site-speciﬁcally-conjugated ADC with a cleav-
able dipeptide linker that is stable in circulation and a DNA-
targeting PBD payload. Upon target binding, the ADC-receptor
complex is internalized and trafﬁcked to the lysosome where
proteolytic cleavage of the linker occurs. The PBD payload is
released and diffuses into the nucleus of the cell, where it binds
DNA with high intrinsic afﬁnity and induces programmed cell
death. Preclinical data demonstrated binding, internalization
and rapid lysosomal trafﬁcking by microscopy analyses. Fur-
thermore, apoptotic processes were assessed and increased:
gamma-H2AX phosphorylation, increased cleaved PARP and
Casp-3 activity were all demonstrated in a dose-dependent
manner. Next, cytotoxic activity in a panel of AML cell lines
showed activity in the majority of cell lines, also taking MDR
status and receptor expression into account and benchmarking
the IC50 levels of 33A to gemtuzumab ozogamicin. Cytotoxic
activity was also assessed in MDR positive and negative in vivo
models and primary patient samples. Subsequently, monother-
apy (33A-001) Phase 1 studies were initiated. Pharmacokinetic
analysis showed target-mediated disposition and rapid ADC
clearance. 91% of the patients had blast reduction at doses
of40 mg/kg. A dose-dependent blast clearance rate was
observed. At doses >40 mcg/kg leukemic clearance occurred,
but on-target myelosuppression resulted in a slower count
recovery of the patients. The optimal monotherapy dose for
further study was therefore determined at 40 mg/kg. Treatment
emergent AEs were mostly related to on-target myelosuppres-
sion, while limited off-target toxicity was observed. Next,
Phase 1 clinical studies with 33A in combination with hypo-
methylating agents (HMA) were evaluated based on data sug-
gesting that HMAs sensitize cancer cells to cytotoxic agents.
Both, azacitidine and decitabine increased CD33 levels on leu-
kemic blasts. Synergism of azacitidine and 33A was demon-
strated by increased levels gH2AX and PARP-mediated cell
death of AML cells. Also in vivo data supported this synergis-
tic effect. The Phase 1 results indicated that 33A at a dose of
10 mg/kg C HMA may provide a favorable balance of activity
and tolerability in older AML patients. Durable remissions
were observed during this study: the 65% CR C CRi rate
more than doubles what is expected from HMA alone. The
median overall survival rate has not been reached yet at the
time of this interim analysis (72% of patients is still alive).
Future studies include a Phase 1/2 study in front-line higher-
risk myelodysplastic syndrome with 33A C azacitidine and a
pivotal Phase 3 study for 33A C HMA in older AML patients
is scheduled for 2016.
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Early clinical development of mirvetuximab
soravtansine (IMGN853) for platinum-resistant
epithelial ovarian cancer
Charles Morris (ImmunoGen) discussed the folate receptor
a-directed maytansinoid ADC mirvetuximab soravtansine,
which has shown encouraging initial evidence of activity in
patients with platinum resistant ovarian cancer in an ongoing
Phase 1 clinical trial. Dr. Morris discussed the emerging clinical
data, as well as the important contribution of clinical pharma-
cokinetics and biomarker-based patient selection to establish-
ing an appropriate dosing regimen and target patient
population.
Clinical update on sacituzumab govitecan (IMMU-132)
in the treatment of advanced triple-negative breast
and lung cancers
Cynthia Sullivan (Immunomedics) gave a clinical update on
sacituzumab govitecan (IMMU132) in the treatment of
advanced triple-negative breast cancer (TNBC) and lung can-
cers (SCLC and NSCLC). IMMU132 is a RS7-3G11-based,
ﬁrst-in-class ADC, site-speciﬁcally conjugated to a moderately
toxic SN-38 drug using a pH-sensitive linker and targeting the
pan-epithelial cancer antigen Trop2/EGP-1. The antigen shows
a broad expression in many different cancers and is a prognos-
tic indicator in certain cancers. The RS7-3G11 antibody binds
many human solid tumors, such as breast, lung, colon, renal
prostate, and urothelial tumors and is known to internalize
upon binding. The antibody and the ADC also have immuno-
therapy functions (ADCC). IMMU132 has an average drug-to-
antibody ratio (DAR) of »7.6. IMMU132 speciﬁcity was deter-
mined comparing double strand breaks in Trop2 positive and
negative cell lines, in which only the Trop2C cell lines showed
double strand breakage upon selective delivery of SN-38. Also,
in vivo efﬁcacy was shown in various human tumor xenografts
expressing different Trop2 levels. Activity was achieved in
patients that relapsed after multiple prior therapies, accompa-
nied with manageable toxicities (less than the parental payload,
irinotecan). Next, IMMU132 clinical Phase 1/2 studies on
relapsed/refractory metastatic TNBC, metastatic NSCLC, meta-
static SCLC, and metastatic urothelial cancer were discussed.
The studies showed promising durable activity for all indica-
tions, with some responses exceeding 14 months. Median over-
all survival has not been reached yet. IMMU132 has an
acceptable safety proﬁle in heavily pretreated patients with
diverse solid cancers. Dose-limiting neutropenia and rare cases
of severe diarrhea were observed. Also, repeated doses can be
administered over many months without evoking interfering
host anti-IMMU132 antibodies. For the future, among other
indications, a Phase 3 trial for mTNBC, and continued Phase 2
trials in lung and urothelial cancers are expected.
Development of immunoliposomes -next generation
ADC formats
Daryl Drummond (Merrimack) then discussed the develop-
ment of immunoliposomes in next generation ADC formats.
Firstly the advantages of the Merrimack nanotechnology were
presented, such as 1:1 drug-to-lipid ratio by weight, facilitating
30.000–150.000 drug molecules per liposome. In vivo stability
and long circulating PK are critical to successful immune-tar-
geted nanoparticle drug delivery, and to reach maximum accu-
mulation at tumor site it needs at least 24 hour stability. MM-
398 payload delivery with sustained intratumor levels of pay-
load was presented. Next, data was presented on MM-302, a
pegylated immunoliposome payloaded with doxorubicin and
targeting ErbB2. When deciding on the type of payload, inter-
nalization and processing of the liposome and kinetic rates
were all taken into account, since these affect the potency of
drug. Doxorubicin could rapidly cross the plasma membrane
and demonstrated a favorable PK. The enhanced permeability
and retention effect in tumor endothelium provide the initial
level of targeting for nanotherapeutics. To further improve tar-
geting, the optimal scFv afﬁnity and number per liposome is
determined for a target. For instance, for HER2 increased scFv
afﬁnity and number of scFv molecules on the liposome allows
to expand treatment to patients with 1C and 2C HER2 expres-
sion. Currently, the focus of MM-302 in the treatment land-
scape is 3rd or 4th line of treatment in HER2C metastatic breast
cancer patients. When combining trastuzumab and MM-302
preclinical data supported enhanced activity of the combina-
tion over single agents. The MM-302 Phase 1 efﬁcacy study in
patients receiving 30 mg/m2 MM-302 resulted in 11% ORR,
21% CBR and mPFS of 7.6 months in comparison to the histor-
ical 3.3 months. Enhanced efﬁcacy was found in anthracycline
na€ıve patients (24% ORR, 28% CBR, 11 mPFS). MM-302
monotherapy demonstrated an acceptable safety proﬁle with
fatigue and nausea being the most prevalent AEs. In total 26%
treatment emergent AEs were apparent of which neutropenia
was most common and 4.3% of the patients were experiencing
severe AEs leading to treatment discontinuation. No treat-
ment-related deaths were observed in this study. Also, no car-
diac events with MM-302 monotherapy were noted. The Phase
2 study HERMIONE is now open and enrolling anthracycline-
na€ıve patients that progressed on pertuzumab and TDM-1.
Lifastuzumab vedotin clinical activity in platinum
resistant ovarian cancer and non-small cell lung
cancer
Final speaker of this special ADC track was Eric Humke (Gen-
entech) who talked about clinical activity of Lifastuzumab
vedotin in platinum-resistant ovarian cancer and NSCLC.
Lifastuzumab Vedotin is an ADC targeting NaPi2b. The dis-
covery of NaPi2b as a possible drug target was discussed and
the target appeared highly expressed in lung, ovarian, and thy-
roid tumors as was indicated by RNA screen and conﬁrmative
IHC data. NaPi2b is a multi-transmembrane, sodium-depen-
dent phosphate transporter normally expressed in lungs, testis,
salivary gland, thyroid gland, small intestine, mammary gland,
and uterus and is involved in transcellular absorption of inor-
ganic phosphate. However, NaPi2b overexpression is believed
to be not carcinogenic itself. Lifastuzumab vedotin consists of a
mc-vc-PABA-MMAE linker conjugate that showed preclinical
target-directed cytotoxicity in lung and ovarian xenograft mod-
els, but also causes toxicity indicated by some bone marrow
and hematological changes in a dose-dependent manner. Next,
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prevalence, incidence, and division of lung cancer subtypes
were discussed. NaPi2b is commonly overexpressed in the non-
squamous histologic subtype and anti-NaPi2b is now being
explored in those patients without targeted therapeutic options.
There is a high unmet need for these patients, of which most
undergoing palliative treatment with a PFS of 2–3 months and
an OS <1 year. A high unmet need also exists for ovarian can-
cer patients, who also mostly receive palliative treatment and
have PFS of 3–4 months and an OS of approximately 1 y. Com-
panion diagnostics were developed along with the Phase 1
study. This clinical trial indicated that lifastuzumab vedotin
was well-tolerated, dose limitations were not due to target
expression on normal tissue and clinical toxicities were mainly
antigen-independent (e.g., neutropenia, peripheral neuropathy
fatigue, nausea, and liver function abnormalities). The study
showed signiﬁcant anti-tumor activity in ovarian (41% PR,
53% CBR) and some activity in NSCLC (0% CR and 20% CBR)
IHC 2C/3C patients. Some CT scan response results of both
cancer types were shown. Based on these Phase 1 results, 3 clin-
ical studies have now started; a Phase 2 trial in platinum-resis-
tant ovarian cancer, a Phase 1b trial in platinum-sensitive
ovarian cancer and a new expansion trial in NSCLC.
Special session: The antibody society
Janice M. Reichert
Antibodies to watch in 2016
Janice M. Reichert, 2015 President of The Antibody Society,
discussed the beneﬁts of participation in The Antibody Society,
and gave an update on the Society’s numerous activities, which
include the organization and promotion of antibody-related
conferences, publication of meeting previews and proceedings,
and organization of a special issue of Protein Engineering,
Design & Selection dedicated to antibody-related articles. She
encouraged the audience to visit the Society’s web page (www.
antibodysociety.org) to become a member and to access resour-
ces maintained by the Society, including a comprehensive table
of therapeutic monoclonal antibodies approved or in review in
the European Union or the United States.
Dr. Reichert then discussed the clinical development and
approval of antibodies in the biopharmaceutical industry’s
pipeline. She noted that 2015 was an extraordinary year for ﬁrst
marketing approvals of antibody therapeutics. The number of
novel antibody therapeutics that received a ﬁrst marketing
approval in 2015 exceeded expectations, with 8 (alirocumab
(Praluent), elotuzumab (Empliciti), evolocumab (Repatha),
daratumumab (Darzalex), dinutuximab (Unituxin), idaruci-
zumab (Praxbind), mepolizumab (Nucala), necitumumab
(Portrazza)) granted their ﬁrst approval as of late December. A
total of 9 antibody therapeutics were granted a ﬁrst US
approval in 2015, including all 8 antibodies noted above as well
as secukinumab (Cosentyx), which received a ﬁrst approval in
Japan in 2014. In the European Union, the European Commis-
sion also granted marketing approvals to 9 antibody therapeu-
tics in 2015, including 5 antibodies noted above ((alirocumab
(Praluent), evolocumab (Repatha), dinutuximab (Uni-
tuxin), idarucizumab (Praxbind), mepolizumab (Nucala))
and 4 products that had been previously approved in another
country. The increase in the number of antibodies gaining ﬁrst
approvals is due at least in part to the larger number of Phase 3
candidates (53 as of late 2015 vs. 39 as of late 2014).
In projecting events that might occur in 2016, Dr. Reichert
noted that 7 novel antibody therapeutics (begelomab, bezlotox-
umab, brodalumab, ixekizumab, obiltoxaximab, sarilumab,
reslizumab) are undergoing regulatory review as of December
2015, and thus may gain their ﬁrst approvals in 2016.29 Of the
53 Phase 3 candidates, transitions to regulatory review by the
end of 2016 are projected for 8 (atezolizumab, benralizumab,
bimagrumab, durvalumab, inotuzumab ozogamicin, lebrikizu-
mab, ocrelizumab, tremelimumab). Other “antibodies to
watch” include 15 candidates (bavituximab, bococizumab,
dupilumab, fasinumab, fulranumab, gevokizumab, guselkumab,
ibalizumab, LY2951742, onartuzumab, REGN2222, roledumab,
romosozumab, sirukumab, Xilonix) undergoing evaluation in
Phase 3 studies that have estimated primary completion dates
in 2016. The increase in the number of mAbs in Phase 3 studies
is expected to drive a trend toward ﬁrst approvals of »6–8 new
mAbs per year. However, the sustainability of this approval
trend depends on veriﬁcation of expected increases in potency
of engineered antibodies, antibody-drug conjugates and bispe-
ciﬁc antibodies, and the validity of the novel targets.
Town hall forum: Antibody drug nomenclature: What
is INN a name?: WHO has been changing them?
Paul Carter
In 2014 the World Health Organization (WHO) introduced
new deﬁnitions for the assignment of antibody international
nonproprietary names (INN). A modiﬁcation of the existing
deﬁnitions was required because advances in antibody engi-
neering have made classiﬁcation into the current 3 main anti-
body groups (i.e., chimeric, humanized and human) unclear.
Unfortunately the new deﬁnitions suffer from several major
limitations that make them unworkable.49 The purpose of the
town hall forum on antibody drug nomenclature was to update
the conference delegates on changes to the INN deﬁnitions, dis-
cuss their consequences, and solicit input on potential next
steps. This session comprised an introductory presentation
from Paul J. Carter (Genentech) based upon a recent publica-
tion by 34 authors from 31 different organizations.49 The pre-
sentation was followed by a panel discussion in which input
was solicited from the audience of conference delegates. The
panelists were Matthew P. Baker (Abzena), Max Vasquez
(Adimab), Andreas Plu€ckthun (University of Z€urich) and
Markus Enzelberger (MorphoSys).
As discussed by Dr. Carter, the WHO established the INN
system in 1950 to provide a unique (generic) name to identify
each pharmaceutical substance. This system serves the impor-
tant function of providing clear identiﬁcation, and safe pre-
scription and dispensing of medicines to patients. Additionally,
the INN system supports communication and exchange of
information among health professionals and scientists world-
wide. The WHO selects INNs based upon the advice of an
expert advisory panel.
The “-mab” stem was introduced in 1990 to indicate mono-
clonal antibody-based therapeutics. Substems were then
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developed in 1997 to describe the antibody origin. The most
widely used of these species origin substems are: -xi- for chime-
ric, -zu- for humanized and -u- for human. The origin sub-
stems were developed to classify antibodies based upon their
“humanness,” and with the assumption that humanness corre-
lates with immunogenicity in patients. Now, nearly 20 y after
this system was ﬁrst introduced, it is appreciated that immuno-
genicity is a complex multi-factorial problem that is impacted
by many parameters beyond amino-acid sequence with no clear
sequence-identity threshold for immunogenicity.5,50 Thus, the
antibody origin substem may have outlived its original purpose.
New INN deﬁnitions for antibodies were undoubtedly
needed as the old deﬁnitions had become outdated by rapid
progress in antibody technologies. These technological changes
include additional methods for humanizing antibodies, an
increasing diversity of technologies for discovering human anti-
bodies, and the widespread use of engineering to improve the
therapeutic potential of antibodies. The creation of a new and
robust naming system for antibody drugs is an exceptionally
difﬁcult undertaking, especially as technologies for antibody
engineering continue to evolve. This challenge is exacerbated
by the ever-expanding repertoire of bispeciﬁc and multispeciﬁc
antibodies that are also entering clinical development.
The most recent (2014) WHO deﬁnition of chimeric anti-
bodies was presented51:
“A chimeric antibody is one for which both chain types are chime-
ric as a result of antibody engineering. A chimeric chain is a chain
that contains a foreign variable domain (originating from one spe-
cies other than human, or synthetic or engineered from any species
including human) linked to a constant region of human origin. The
variable domain of a chimeric chain has a V region amino acid
sequence which, analyzed as a whole, is closer to non-human spe-
cies than to human.”
Similarly, the 2014 WHO deﬁnition for humanized antibod-
ies was also described51:
“A humanized antibody is one for which both chain types are
humanized as a result of antibody engineering. A humanized chain
is typically a chain in which the complementarity determining
regions (CDR) of the variable domains are foreign (originating
from one species other than human, or synthetic) whereas the
remainder of the chain is of human origin. Humanization assess-
ment is based on the resulting amino acid sequence, and not on the
methodology per se, which allows protocols other than grafting to
be used. The variable domain of a humanized chain has a V region
amino acid sequence which, analyzed as a whole, is closer to human
than to other species”
Notably, a deﬁnition for human antibodies is missing from the
2014 WHO guidance document on INN.51 As for sequence analy-
sis, comparison to human immunoglobulin heavy or light chain
germline V-gene segments (IGHV, IGKV or IGLV) should be
done with the Immunogenetics Information System

(IMGT

)
DomainGapAlign tool (www.imgt.org). This was clariﬁed during
an open session of the WHO Expert Group in April 2015. The
WHO INN drug names are used worldwide, with the exception
of the USA. In the USA, the American Medical Association
(AMA) assigns nonproprietary drug names known as United
States Adopted Names (USAN). The drug name application
processes are separate for WHO-INN and AMA-USAN.52, 53
However, the WHO and the AMA work in close collaboration;
thus, INN and USAN are commonly, but not invariably identi-
cal. The AMA has provided USAN/INN requirements for
monoclonal antibodies that includes deﬁnitions of chimeric,
humanized and human antibodies. 54 These antibody deﬁni-
tions are based upon the sequence identities of their variable
regions to human heavy or light chain germline V-gene seg-
ments available in the IMGT

reference database: <85% for
-ximab with 85% being either -zumab or –umab. 54
Next, the impact of the new INN rules was considered. Most
of the approved humanized antibodies are predicted to be “chi-
meric” or “mixed” under the new rules. Thus, assignment of
INN names using the 2014 deﬁnitions is often inconsistent
with the previous INN names, as well as with decades of scien-
tiﬁc literature. Approved human antibodies are likely to retain
their “human” classiﬁcation under the new INN rules. This has
created signiﬁcant inconsistency among antibodies that are, in
fact, similarly “human”, yet which have been assigned different
substem names due to the timing of their approval. In addition,
some antibodies cloned from human subjects bear many
somatic hypermutations (e.g., anti-HIV antibodies) and
have <85% sequence identity with their closest human germ-
line V-gene segments; yet they would fall within the deﬁnition
of “chimeric”. Thus, it is unclear how antibodies should be clas-
siﬁed, as human or humanized, since a 85% sequence-identity
threshold is being used for both. One justiﬁcation for this clas-
siﬁcation is that human antibodies are cloned from human sub-
jects whereas humanized antibodies are engineered, regardless
of their origin. However, this is inconsistent with the stated
goal of the assessment being based upon a resulting sequence
and not the methodology that was used to generate it.
Dr. Carter discussed 8 of the major limitations of the 2014
INN antibody naming deﬁnitions: 1) The deﬁnitions do not
allow researchers to determine reliably how an antibody will be
classiﬁed; 2) The linking of sequence homology deﬁnitions to
an evolving database of germline V-gene segments, makes the
assignment of the origin substems a moving target; 3) It is pos-
sible for antibodies to be immunogenic if they are encoded by
human germline V-gene sequences that are absent from a given
patient’s germline. Thus deﬁnitions that rely solely on similar-
ity to germline V-gene sequences may provoke a false impres-
sion of their propensity for immunogenicity; 4) The deﬁnitions
are inconsistent with several decades of precedence in naming
antibodies in the scientiﬁc literature including many previously
assigned INN names, i.e., the deﬁnitions are incompatible with
existing names; 5) There is no WHO deﬁnition available for
what makes an antibody “human” or how a “human” antibody
differs from a “humanized” antibody;51 6) The sequence-iden-
tity threshold of 85% used in the AMA antibody deﬁnitions to
determine human and humanized from chimeric antibodies is
arbitrary, and the relationship to immunogenicity has not been
established; 7) The antibody J region forms a critical part of all
V domains, but is not included in the INN process; 8) The
extent to which an antibody falls within the deﬁnition of
human/humanized will be signiﬁcantly impacted by the iden-
tity of the CDRs to the closest human germline V gene segment
in the IMGT

database.
Some options for a new INN antibody system were consid-
ered, such as developing new substems (e.g., -sy- for synthetic
or -e- for engineered). An alternative option of dropping the
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origin substem entirely (i.e., use the -mab stem only) was also
considered.
The presentation concluded with the message that dialog
between the WHO INN Expert Group and key stakeholders is
urgently needed to develop a more robust INN system for nam-
ing new antibody drugs. The WHO open session with INN
stakeholders in April 2016 was identiﬁed as an excellent oppor-
tunity to initiate such a dialog.
The panel and audience engaged in a lively discussion. In
general, participants strongly endorsed the notion that the
2014 antibody INN naming convention has major limitations
and urgently needs revision. Audience members recounted a
number of examples of nonproprietary names that are illogical
in comparison to the prevailing nomenclature. There was very
strong support for engaging in a discussion with the WHO to
encourage it to address the ﬂaws in the current system. Several
participants voiced the opinion that is important that new deﬁ-
nitions also govern therapeutic antibody INNs assigned under
the 2014 deﬁnitions. Several creative suggestions were made for
a new naming system. As mentioned, these included dropping
the origin substem completely and using only the -mab stem;
however, no clear agreement was reached in the time allotted.
Thursday December 10, 2015: Track A: Building
comprehensive IgVH-gene epertoires: Discovering,
conﬁrming & cataloging new germline IgVH genes
Matthias Pauthner
The session was chaired by Jamie K. Scott (Simon Fraser
University), who brieﬂy introduced the current research ques-
tions pursued in the rather new ﬁeld of Ig repertoire sequencing
or ‘antibody-omics’.
A transcriptome-based comparison of the heavy chain
germline genes of the C57 BL/6 and BALB/c mouse
strains
Andrew Collins (University of New South Wales) started the
session by presenting a transcriptome-based comparison of Ig
heavy (IgH) germline genes in C57 BL/6 and BALB/c mice.
Since mice are both the classic subject of immunological
research and the go-to model system for the generation of
mAbs, a detailed analysis of murine Ig germline genes and anti-
body repertoires in commonly used strains is highly relevant.
In the ﬁrst part of his talk, Dr. Collins presented 2 454 deep
sequencing data sets of the C57 BL/6 (»21 k sequences) and
BALB/c (»15 k sequences) IgM naive repertoires, sequenced
from murine splenocytes. The accurate calculation of muta-
tional frequencies for mature Ab genes from Ab germline genes
is heavily reliant on complete germline gene databases for any
given species, and still presents a big challenge in the ﬁeld.
When both datasets were queried against the IMGT database
(www.imgt.org), the de facto reference database for such appli-
cations, C57 BL/6 reads aligned well with deposited IgVH
germline alleles and showed narrow mutational distribution
patters, as expected for naive IgM sequences. In the BALB/c
data set, on the other hand, numerous groups of apparently
strongly sequences (e.g., 188 reads calculated to be 18 nt diver-
gent from IgVH1–1801), revealed both substantial differences
between the 2 mouse strains as well as the absence of correct
BALB/c IgVH germline genes deposited in IMGT - thus caus-
ing falsely high mutational frequencies. In summary, only 50%
of detected BALB/c IgVH alleles were annotated in the IMGT
database, »30% were present in the VBASE2/NCBI database
and »20% were entirely novel. Further, in-between the
C57 BL/6 and BALB/c IgVH repertoires (99 and 164 detected
alleles, respectively), only 5 were shared.
Dr. Collins then dove into the question of how mice build
their effective Ig repertoire, given that they have a signiﬁcantly
lower count of total B cells than the theoretical repertoire size
arising from combinatorial and junctional diversity (108 vs.
1012, respectively). While combinatorial diversity is comparable
between human and mice, N-nucleotide addition varies greatly.
In humans, on average 7 nt are added to VD and DJ junctions,
stochastically introducing a least one fully N-nucleotide
encoded amino acid, while mice on average only add 3 nt, 83%
of which merely complete codons that are partially germline
encoded, and therefore strongly pre-determined by the redun-
dancy of the genetic code. Additionally, mice do not compen-
sate the diminished junctional diversity through somatic
hypermutation: »80% of all murine IgG sequences carry 4 or
less mutations while the overwhelming majority of human IgG
sequences are mutated from their respective germline genes.
In conclusion, Dr. Collins’ ﬁndings show that there are
strong differences between inbred mouse strain Ig repertoires
and suggest that the underlying reason is, that mice compensate
for reduced repertoire diversity by relying on a more adapted,
germline encoded repertoire, which is likely anticipatory of the
commonly encountered pathogens the respective mouse strain
co-evolved with. This ﬁnding has direct implications on choos-
ing appropriate animal systems for mAb generation, as well as
murine immunization studies in general.
Transcriptional control of V(D)J recombination
Ann Feeney (The Scripps Research Institute) discussed the
observation that V genes are not equally likely to be utilized,
and explained the underlying mechanisms steering VH gene
rearrangement frequencies, which are strongly inﬂuenced by
the presence of enhancer elements in the IgH locus.
The Ig repertoire of the rhesus macaque
Thomas Kepler (Boston University) discussed his work on
mapping and assembling the IgH locus of a single rhesus
macaque, as well as statistical methods for inferring the correct
germline IgVH genes in antibody repertoire sequencing data-
sets. Both are considered critical steps toward correctly calcu-
lating mutational frequencies and accurately tracking the
development of mAb lineages in rhesus macaques, which will
be especially useful to HIV vaccine design efforts, once
completed.
Somatic and germline genetics of antibody gene
rearrangement
Steering away from animal models, Scott Boyd (Stanford Uni-
versity) discussed human immune repertoire data obtained
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from a cohort of identical twins. He showed that naive B cell
repertoires of identical twins are very similar, whereas their
antigen-experienced memory B cell repertoires are quite differ-
ent. This indicates that it might indeed be possible to predict
the naive B cell repertoire, generated by combinatorial and
junctional diversity, while the memory repertoire is very much
a function of the immunological history of any given person.
Identiﬁcation of novel germline immunoglobulin
alleles in a South African population
In the following talk, Bronwen Lambson (National Institute for
Communicable Diseases) presented on the identiﬁcation of
novel germline Ig alleles in a South African population. Broadly
HIV neutralizing antibodies (bNAbs) differ from strain-speciﬁc
NAbs in that they can neutralize a wide range of global HIV
isolates by targeting functionally conserved epitopes on the
HIV envelope. BNAbs are thought to be a key component of a
protective HIV vaccine, however, only 15–30% of long-term
infected patients develop broadly neutralizing serum responses
and known bNAbs show multiple unusual genetic features
(e.g., high mutation rates, up to »30% (nt), very long HCDR3s,
up to 39aa), calling for novel immunization strategies.
In the ﬁrst part of her talk, Dr. Lambson addressed the ques-
tion of how geographically representative the deposited Ig vari-
able heavy (IgVH) genes in the IMGT reference database
(www.IMGT.org) are, by deep sequencing the germline
encoded IgVH repertoires of 28 HIV-1 infected donors from
the CAPRISA cohort. To that end, DNA was isolated from
donor PBMCs, IgVH genes were ampliﬁed with general VH
subgroup primers using both 454 and Illumina based sequenc-
ing, and the resulting data sets were queried against the IMGT,
Ig-BLAST and Ig-PDB databases. Interestingly, this analysis
revealed 85 entirely novel alleles and 38 alleles that were depos-
ited in the Ig-PDB database. Strikingly, novel alleles were dis-
persed among all VH subgroups, frequently encoded non-
synonymous mutations and more than half of newly identiﬁed
alleles were found in 4 or more donors, suggesting a geographi-
cal bias in the reference database.
Dr. Lambson then investigated IgVH copy number varia-
tions (CNVs) in the CAPRISA cohort as a possible explanation
for the observed increase in IgVH allelic variation. It is known
that some VH genes display CNVs, like the VH1–69 gene, which
is also a commonly used V-gene in HIV bNAbs. To test this
hypothesis, Dr. Lambson determined the copy number of
VH1–69 genes using a Droplet Digital PCR assay, which com-
pares the amount of amplicons of a target gene to a known
genomic reference. Indeed, most CAPRISA donors had 2–4
copies of VH1–69, often possessing a mixture of IMGT, non-
IMGT and novel VH1–69 alleles. To address the question
whether all novel and non-IMGT alleles are actively used in Ig
repertoires, they were queried against antibodies isolated from
the CAPRISA cohort, at least 16 of which in fact utilized novel
and non-IMGT alleles (7 alleles in total). Additionally, the pre-
dicted germline sequences of multiple known bNAb families
more accurately matched novel IgVH alleles.
In the ﬁnal part of her talk, Dr. Lambson addressed the
question if germline IgVH repertoires differ between donors
that did and did not develop broadly HIV neutralizing serum
activity. Interestingly, there was no apparent difference in
IgVH repertoire between the 2 groups, suggesting that vaccine
design efforts do not need to take into account geographical
variations in IgVH germline repertoires, theoretically facilitat-
ing the design of globally applicable immunogens. This work
was published in the Journal of Immunology in 2015.55
Inferring the immune systems dynamics from
high-throughput antibody repertoire sequencing data
As discussed by Gur Yaari (Yale University), despite the huge
promise of high-throughput sequencing of the antibody reper-
toire, extracting valuable biological information from these
large datasets is challenging, and requires continuous develop-
ment of computational tools. Tools were developed to infer an
individual genotype from antibody repertoire sequences, quan-
tify afﬁnity-dependent selection and build a targeting model for
the observed mutation spectrum. The applicability of these
tools in the context of Multiple Sclerosis and Celiac disease was
shown.
Track B: Overcoming resistance to clinical
immunotherapy
Jenny Yeung
Chaired by Louis Weiner (Georgetown University Medical
Center), the last Track B session of the meeting focused on how
resistance to immunotherapy might be overcome.
Mechanisms of resistance to immunotherapy
Most of the successes using immunotherapy for solid tumors
and hematologic malignancy have been in melanoma, using
active immunotherapies (cytokines and immune checkpoint
inhibitory antibodies) and lymphoproliferative diseases using
passive immunotherapies including unmodiﬁed and modiﬁed
antibodies or related structures. As discussed by Kim Allyson
Margolin (Stanford University Medical Center), the immune
response depends on a complex network of tumor cells, various
leukocyte populations, stromal and vascular endothelial cells in
a tumor immune microenvironment that may change over
time, in response to therapy and in different organ sites. The
identiﬁcation of factors that can be modulated to overcome
intrinsic resistance, pre-empt acquired resistance, and avoid
dangerous toxicities, including immune-based injury, will be
critical.
Targeting immune checkpoints in genitourinary
cancers: Rationale and current data
Ipilimumab, an anti-CTLA-4 antibody, was the ﬁrst immune
checkpoint inhibitor to be approved for the treatment of mela-
noma. As discussed by Nizar M. Tannir (MD Anderson Can-
cer Center), this has opened a new ﬁeld termed “immune
checkpoint blockade.” Trials combining nivolumab, an anti-
PD-1 antibody, and ipilimumab are ongoing in metastatic renal
cell cancer (mRCC) and bladder cancer. In a Phase 1 trial in
patients with bladder cancer, MPDL3280A, a PD-L1 antibody,
produced 48% ORR in patients whose immune cells expressed
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PD-L1. Research efforts are focused on the identiﬁcation of
predictive biomarkers of response, mechanisms of innate and
acquired resistance, optimal duration of therapy, and best com-
binatorial strategies.
Targeting cancer’s fragile strengths to overcome
immune evasion and promote effective
immunotherapy
Antagonistic immune checkpoint antibodies have been very
successful for some malignancies, however their effects are not
found in all patients and their effects may not be long lasting in
others. As discussed by Louis Weiner (Georgetown University
Medical Center), understanding how tumor cells develop resis-
tance to these therapeutic agents will enable therapeutic target-
ing of resistance mechanisms. Identiﬁcation of new agents and
strategies that can be used alone or in combination with
immune checkpoint inhibitory antibodies would help to
improve response rates.
An in vivo synthetic lethal shRNA screen was carried out
using a murine breast cancer model to identify genes that
protected tumors grown in wild-type immune-competent
mice compared to immune-compromised mice. It was
hypothesized that immune selection pressure favored in
vivo expansion or contraction of malignant cells upon
knock-down of critical genes. A shRNA library was intro-
duced into the murine EO771 breast carcinoma cells that
were transplanted into C57 BL/6 mice or C57 BL/6-SCID
mice. Analyses of the relative expression of shRNA in
tumors, which grew in either wild-type or SCID mice, iden-
tiﬁed 165 hits that showed adaptive immune selection pres-
sure for cells with speciﬁc gene knock-downs. Gene knock-
downs leading to under-representation in tumor cells grow-
ing in wild-type mice were genes that promoted survival in
presence of immune selection pressure. Gene knock-down
that led to over-representation in cells growing in wild-type
mice represented genes that reduced survival in presence of
immune selection pressure.
Validation of this model system was demonstrated by iden-
tiﬁcation of genes with established roles in cancer immunity.
CD47 is under-represented in wild-type mice compared to
SCID mice where CD47 knock-down cells were rejected in
EO771 tumors. CD47 is often overexpressed in tumors cells,
which results in inhibition macrophage phagocytosis. The puta-
tive Tex9 tumor antigen was over-represented in wild-type
mice, where knock-down of Tex9 led to tumors that survived
longer in wild-type mice compared to SCID mice. Furthermore,
pathway analysis of the data identiﬁed TGF-b as a central regu-
lator of the immune response. Knock-down of TGF-b in
EO771 tumor cells reduced tumor growth and promoted sur-
vival of the wild-type mice compared to immune-compromised
mice.
This work demonstrated that a novel functional genomics
approach enabled identiﬁcation of individual genes that regu-
lated the response of the tumor to immune selection pressure.
Results validated CD47 and TGF-b as targets for immunomo-
dulation in cancer therapy and identiﬁed new immunothera-
peutic targets and can aid development of future combinatorial
therapies.
Radiation-induced immunogenic modulation to
enhance T cell and monoclonal antibody therapy of
cancer
James W. Hodge (National Cancer Institute/National Insti-
tutes of Health) discussed the various uses of radiation therapy,
which is used for treatment of many malignancies and is aimed
at tumor destruction by inducing selective cell death of tumor
cells. Local and systemic radiation therapy may be combined
with immunotherapy to increase anti-tumor activity through
immunogenic modulation. Here, the phenotype of the tumor is
altered by radiation therapy and renders them more sensitive
to killing by immune system.
Cancer vaccine efﬁcacy can be improved by radiation ther-
apy. Radiation therapy changes components of the antigen
processing machinery such as proteasome subunits, peptide
transporters and protein chaperones. These can result in upre-
gulation of MHC class I as well as translocation of calreticulin,
which facilitates T cell-mediated killing. Preclinical data
showed that palliative levels of 153-Sm radionuclide increased
expression of FAS and ICAM-1, tumor associated antigens
such as PSA ad PSMA, as well as increased MHC class I expres-
sion, which led to increased antigen-speciﬁc cytotoxic T cell
killing. In the clinical studies, QUARDAEMT, a 153-Sm con-
taining therapeutic agent for palliation of bone metastasis com-
bined with the PSA-TRICOM vaccine for hormone refractory
prostate cancer, demonstrated that the combination therapy
increased progression free survival to 3.7 months compared to
1.7 months with QUADRAMET alone.
Finally, radiation therapy was also shown to upregulate ther-
apeutic targets and sensitized them to monoclonal antibody
therapy. The targets of cetuximab (EGFR), rituximab (CD20)
and trastuzumab (HER2) were all upregulated after radiation
treatment. Upregulation of HER2 by doses as low as 2 Gy were
maintained over 96 hours, resulted in better trastuzumab-medi-
ated ADCC, and sensitized them to the anti-proliferative effects
of trastuzumab. Upregulation of HER2 was also found in tri-
ple-negative breast cell lines, which are normally not sensitive
to anti-HER2 therapy. These effects of radiation therapy would
be particularly useful for tissues that express low amounts of
the antigen of interest, could potentially sensitize tumors resis-
tant to monoclonal antibody therapy, plus increase the number
of patients eligible for targeted therapy.
Leveraging clinical learnings and patient tailoring to
enable next generation ADC success
Alan Rigby (Synta Pharmaceuticals) discussed HSP90-drug
conjugates (HDCs). HSP90 is a molecular chaperone that regu-
lates post-translational folding, stability and function of protein
substrates or client proteins. These client proteins may have
important roles in cell growth, differentiation and survival.
HSP90 accounts for 4–6% of total cellular proteins. The confor-
mation and post-translational modiﬁcation of HSP90 in tumor
cells enables higher binding afﬁnity, and thus tumor retention
to small molecule HSP90 inhibitors, such as ganetespib. HSP90
inhibitors selectively kill tumor cells through this retention/
accumulation in the tumor cell by preventing requisite interac-
tions with oncogenic client proteins, which in turn leads to
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their degradation in the proteasome. Leveraging the learnings
of ganetespib, Synta has developed HDCs with an HSP90
inhibitor as the tumor-targeting arm that is conjugated to an
anticancer payload through a cleavable linker. HDCs have
advantages over ADCs because they are smaller molecules
(molecular weight of 550–1500) that target intracellular HSP90
in many tumor types. Their small size enables them to enter
cells through passive diffusion or through an activated trans-
porter. This can overcome issues with low antigen density that
can be encountered by ADCs, and provides a novel approach
to improving the therapeutic index that continues to plague
ADC therapies.
STA-12-8666 is a ﬁrst-in-class HSP90 inhibitor SN-38
drug conjugate developed by the Synta HDC platform. SN-
38 is the active metabolite of irinotecan, a widely used potent
topoisomerase 1 inhibitor. This ﬁrst-in-class HDC demon-
strated an improved therapeutic window and better efﬁcacy
in a number of cancer models, including a cisplatin-resistant
small lung carcinoma model, a chemo-resistant pancreatic
PDX model and several other cancer PDX models. STA-12-
8666 was able to induce durable tumor regression compared
to HSP90 inhibitor or irinotecan alone by increased reten-
tion times in the tumors. When the tumors in these models
relapsed, retreatment with the HDC demonstrated retained
sensitivity.
HDCs are able to increase on target exposure of the anti-
cancer payloads, resulting in sustained ‘on target’ delivery of an
active payload into tumors. As demonstrated for STA-12-8666
it appears that HDCs have improved tumor access, tumor pen-
etration and residualization compared to ADCs. To further
probe and validate the HDCs mechanism of tumor retention
and its contribution to target exposure, which is responsible for
the durable responses observed in several PDX animal studies
an HSP90-targeted imagining agent is under development. Pre-
clinical toxicology studies also support a superior safety proﬁle
of the HDC vs. combination therapy at clinically translatable
doses.
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